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NICE has accredited the process used by the British Association 
of Dermatologists to produce guidelines. The renewed 
accreditation is valid until 31 May 2021 and applies to guidance 
produced using the process described in Updated guidance for 
writing a British Association of Dermatologists clinical guidance – 
the adoption of the GRADE methodology 2016. The original 
accreditation term began on 12 May 2010. More information on 
accreditation can be viewed at www.nice.org.uk/accreditation. 
 




The overall objective of the guideline is to provide up-to-date, evidence-based 
recommendations for the management of pemphigus vulgaris (PV). The document aims to 
update and expand on the previous guidelines by:  
• offering an appraisal of all relevant literature from January 2000 up to May 2016, 
focusing on any key developments 
• address important, practical clinical questions relating to the primary guideline 
objective. 
• providing guideline recommendations and, where appropriate, with some health 
economic implications 
• discussing potential developments and future directions 
 
The guideline is presented as a detailed review with highlighted recommendations for 
practical use in the clinic (see section 29), in addition to an updated Patient Information 





This guideline does not cover other forms of pemphigus. 
 
 
2.0 STAKEHOLDER INVOLVEMENT AND PEER REVIEW 
 
The guideline development group (GDG) consisted of consultant dermatologists and a 
clinical nurse specialist in medical dermatology. One of the dermatologists is also an oral 
medicine specialist. The draft document was circulated to the British Association of 
Dermatologists (BAD) membership, British Dermatological Nursing Group (BDNG), Primary 
Care Dermatological Society (PCDS), Pemphigus Vulgaris Network and PEM Friends (UK) 
for comments, which were actively considered by the GDG, and peer-reviewed by the 
Clinical Standards Unit of the BAD (made up of the Therapy & Guidelines Sub-committee) 





This set of guidelines has been developed using the BAD recommended methodology1 and 
with reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) 
instrument [www.agreetrust.org].2 Recommendations were developed for implementation in 
the NHS using a process of considered judgment based on the evidence. PubMed, 
MEDLINE, EMBASE and LILACS databases were searched for PV from January 2000 up to 
May 2016; search terms and strategies are detailed as a web appendix. Additional relevant 
references were also isolated from citations in reviewed literature. All identified titles were 
screened and those relevant for first-round inclusion were selected for further scrutiny. The 
abstracts for the shortlisted references were then reviewed by the GDG and the full papers 
of relevant material obtained; disagreements in the final selections were resolved by 
discussion with the entire GDG. The structure of the 2003 guidelines was then discussed 
and re-evaluated, with headings and sub-headings decided; different co-authors were 
allocated separate sub-sections. Each co-author then performed a detailed appraisal of the 
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selected literature with discussions within the GDG to resolve any issues. All sub-sections 




4.0 LIMITATIONS OF THE GUIDELINE 
 
This document has been prepared on behalf of the BAD and is based on the best data 
available when the document was prepared. It is recognized that under certain conditions it 
may be necessary to deviate from the guidelines and that the results of future studies may 
require some of the recommendations herein to be changed. Failure to adhere to these 
guidelines should not necessarily be considered negligent, nor should adherence to these 
recommendations constitute a defence against a claim of negligence. Limiting the review to 
English language references was a pragmatic decision but the authors recognize this may 
exclude some important information published in other languages. 
 
 
5.0 PLANS FOR GUIDELINE REVISION 
 
The proposed revision date for this set of recommendations is scheduled for 2022; where 





PV is an acquired autoimmune disease in which IgG antibodies target desmosomal proteins 
to produce intraepithelial, mucocutaneous blistering. Desmoglein 3 is the major antigen but 
50% to 60% of patients have additional antibodies to desmoglein 1, the antigen targeted in 
pemphigus foliaceus (PF).3-5 Although the pathogenesis of PV is complex, involving multiple 
pathways,6 the underlying antibody profile is a major determinant of the clinical phenotype of 
PV.5,7,8 
 
The average mortality of PV was 75% before the introduction of corticosteroids in the early 
1950s.9 This figure may be an underestimate due to lack of diagnostic criteria, inclusion of all 
subtypes of pemphigus and of other blistering disorders such as bullous pemphigoid, which 
have a better prognosis. However, not all cases of PV have such a dismal prognosis. 
Studies differentiating the clinical phenotypes have shown a lower mortality in patients with 
predominantly mucosal PV (1% to 17%) compared with those with mucocutaneous PV (8% 
to 42%).10-12 Mucocutaneous PV tends to be a more severe disease, proving slower to 
respond to treatment and less likely to achieve remission off-treatment than purely mucosal 
PV.13 
 
6.1 Clinical presentation 
 
The diagnosis of PV should be suspected in any patient with mucocutaneous erosions or 
blisters. The oral mucosa is the first site of involvement in the majority of cases and PV may 
remain confined to the mucosal surfaces or extend to involve the skin (average lag period of 
4 months).14-16 Diagnostic delay is very common when PV is confined to the oral mucosa.17 A 
4 
 
minority will present with cutaneous erosions but oral erosions will, eventually, occur in most 
cases. PV presents across a wide age range with peak frequency in the third to sixth 
decades. 
 
7.0 LABORATORY DIAGNOSIS 
 
Perilesional skin biopsies should be taken for histology and direct immunofluorescence 
(DIF). In patients with isolated oral disease, a histology specimen should be taken from 
perilesional mucosa and a DIF sample taken from an uninvolved area ideally from the buccal 
mucosa.18 Suprabasal acantholysis and blister formation is highly suggestive of PV but the 
diagnosis should be confirmed by the characteristic deposition of IgG and/or complement in 
the intercellular spaces of the epidermison the cell surfaces of epithelial keratinocytes. 
Indirect immunofluorescence (IIF) is less sensitive than DIF19-21 but may be helpful if a 
biopsy is difficult, e.g. children and uncooperative adults. Commercial enzyme-linked 
immunosorbent assays (ELISA) are available for direct measurement of desmoglein 1 and 
desmoglein 3 antibodies in serum. They potentially offer advantages over IIF, such as 
increased sensitivity, but are not helpful in cases in which there are other antigens.22-24 
Therefore, IIF and ELISA should be considered complementary and DIF remains the gold 
standard diagnostic investigation.25 Five millilitres of blood is sufficient for both IIF and 
ELISA. Saliva is potentially a useful alternative to serum for ELISA; there is emerging 
evidence that desmoglein 3 IgG is detectable in saliva by ELISA with a similar sensitivity to 
serum (61% saliva vs. 74% serum).26 
 
In patients with oral pemphigus, an intra-oral biopsy is the optimum but IIF or DIF on a skin 
biopsy may suffice. One study showed that the sensitivity of DIF was 71% in oral biopsies 
compared with 61% in normal skin taken from 28 patients with oral PV.27 Another study 
reported that the sensitivity of DIF was 89% in oral biopsies compared with 85% for IIF.15 If 
there are no skin lesions and a sample for DIF is to be taken from the oral mucosa, the 
buccal mucosa can be exposed by everting the cheek, placing the thumb at the commissure 
and reflecting the corner of the mouth, applying external pressure on the cheek with the 
index finger to present the buccal mucosa. 
  
The transport medium into which samples for DIF are placed varies, including saline, 
Michel’s medium and snap freezing into liquid nitrogen.28 Liquid nitrogen gives good 
preservation of immunoreactants but has practical disadvantages. However, it has been 
shown in one study using matched biopsy specimens that transportation in saline, for up to 
24 48 hours, gave superior results, to liquid nitrogen, providing a more practical and cost-
effective medium for getting samples to the lab.29 Transportation in saline for up to 24 hours 
was optimum29 and Michel’s medium is favoured for longer transportation times.28 
 
 
8.0 FURTHER INVESTIGATIONS 
 
The following additional investigations should be considered prior to commencing treatment:  
full blood count and differential, urea and electrolytes, liver function tests, fasting glucose 
and HbA1C, fasting lipids, antinuclear antibody (differential of pemphigus erythematosus), 
urinalysis, blood pressure, weight, height (children) and a pregnancy test in females at risk of 
pregnancy. Current guidelines on prevention of osteoporosis30 should be followed, so a bone 
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density scan early in the course of treatment may be needed. In anticipation of using an 
adjuvant immunosuppressant, appropriate recommended additional investigations and 
vaccinations should be undertaken. A baseline measure of disease activity (see section 9.1) 
and quality of life, supplemented by IIF and ELISA titres if facilities exist, will be useful for 
disease monitoring and judging treatment responses (see sections 9.0-9.2).  
 
 
9.0 DISEASE MONITORING 
 
Decisions concerning ongoing disease management will be based on making an 
assessment of disease activity. The simplest way of monitoring disease activity is clinically, 
which can be done more objectively by using clinical disease scoring systems. Clinical 
disease activity assessment can be supplemented with immunological measures and quality 
of life scores. 
 
9.1 Disease severity scoring 
 
Numerous disease severity scoring systems exist making it difficult to compare data 
between studies. Two validated severity scoring systems which have become frontrunners 
are the pemphigus disease area index (PDAI) and the autoimmune bullous skin disorder 
intensity index (ABSIS),31-34 each taking 2-5 minutes to complete.32,34 These have also been 
validated for use in oral PV but are inferior to another system, the oral disease severity score 
(ODSS), which may be combined with ABSIS or PVDAI in patients with skin or extra-oral 
mucosal sites.35 
 
It is recommended that disease severity is scored in routine clinical practice. It is essential in 
clinical trials. 
 
9.2 Immunological monitoring 
 
IIF can be used to express the quantity of pemphigus antibodies in serum as a series of 
discontinuous serum dilutions. It is subjective and operator-dependent and the titre depends 
on the substrate used, due to variable amounts of antigen being expressed at different sites. 
In general, mucosal substrates are better for detection of desmoglein 3 antibodies and skin 
better for detection of desmoglein 1 antibodies, with the use of both substrates enhancing 
sensitivity.36 IIF titres can reflect disease activity but the relationship is not perfect and 
examples of active disease with negative IIF or vice versa exist such that IIF cannot be relied 
upon for disease monitoring. Whether IIF using two substrates is more useful for disease 
monitoring is yet to be demonstrated.  
 
Desmoglein 1 and 3 ELISAs are sensitive and specific assays providing an objective and 
quantitative measure of antibody levels. In general, ELISA levels are related to disease 
activity, with desmoglein 1 antibody levels associated with skin severity and desmoglein 3 
levels associated with oral severity.37-41 Titres usually fall with treatment and disease 
remission.40,42-45 Patients followed over time also show fluctuations in ELISA levels that 
mirror disease activity37,41 but as with IIF, the relationship is not perfect: examples of patients 
with inactive disease and high ELISA titres and vice versa are reported,37,42-44 and one study 
found that changes in desmoglein 3 antibody levels did not correlate with clinical activity.43 
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Some of these problems reflect saturation of the ELISAs at higher values which could be 
overcome by increasing the serum dilution.46 
 
The use of sequential salivary anti-desmoglein 3 IgG titres as a biomarker of disease activity 
is an emerging area of interest and titres have recently been shown to reflect oral disease 
activity.26 
 
In general, falling or persistently low and negative IIF or ELISA titres are a good sign; such 
that immunosuppression could be tapered. Rising or persistently high titres should be a 
cause for concern. Where facilities exist to follow titres, the information could be used as an 
adjunct to clinical assessment but due to the imperfections of the assays discussed, good 
clinical judgement remains paramount.  
 
 
10.0 EVALUATING THERAPIES IN PEMPHIGUS VULGARIS 
 
In general, the quality of published data concerning the therapy of PV is poor. There are few 
good quality randomized controlled trials (RCTs). The majority of data is confined to case 
reports and small case series in which PV cases of variable severity may be included, often 
with other subtypes of pemphigus. Follow-up periods are often short, even in the larger trials, 
and dosing schedules vary widely. Trial design is often poor, with different drug 
combinations used in different arms such that any differences in outcomes cannot be 
attributed to a single intervention. Controls are often indirect, involving comparisons of 
remission and mortality rates with historical controls or comparison of maintenance 
corticosteroid doses before and after the addition of a given therapy. A huge number of 
outcome measures and disease definitions have also been used, making comparison 
between studies difficult. Finally, the rarity of PV means recruitment of sufficient numbers of 
patients is challenging; many studies are small and underpowered.  
 
To address some of these issues, the International Pemphigus Committee has produced a 
consensus statement which outlines definitions of important time points and disease 
status.47 In parallel, efforts are being made to use commonly accepted disease severity 
scores.32,33 By using a commonly accepted set of core outcome measures, it is envisaged 
that trial data can be better compared and pooled such that small and underpowered 
individual studies could become of value as it would be possible to include them in larger 
meta-analyses. In addition, it is now widely acknowledged that the rarity of PV means 
cooperative research with multiple recruitment sites are needed to produce successful trials 
with adequate power.48 It has been estimated that to demonstrate a 20% difference between 
interventions with 80% power, a study of more than 196 patients would be needed in PV.49 
Trials such as these, using a set of core outcome measures, are coming into being but at 
present, in most studies, it is difficult to judge the effect of individual drugs and make firm 
treatment recommendations. In these guidelines, we have listed the highest ranking level of 
evidence and given an overall recommendation for each therapy. A summary of treatment 
options is given in section 29. 
 
 




PV is an uncommon and potentially life-threatening disease requiring immunosuppressive 
treatment. It should be managed by secondary care physicians experienced in the treatment 
of autoimmune mucocutaneous diseases. The management of active oral PV with systemic 
therapies should be approached in the same way as the management of active skin disease 
and could be managed by dermatologists where oral medicine expertise is not available. 
 
The management of PV can be considered in two main phases: induction of remission 
and maintenance of remission.  
 
Remission induction: the initial aim of treatment is to induce disease control, defined as 
new lesions ceasing to form and established lesions beginning to heal.47 Corticosteroids are 
the most effective and rapidly acting treatment for PV, hence are critical in this phase. Using 
corticosteroids, disease control typically takes several weeks to achieve (median 3 weeks).50 
During this phase the intensity of treatment may need to be built up rapidly to suppress 
disease activity. Although adjuvant drugs are initiated during this phase in general, their 
immediate therapeutic benefit is relatively limited because of their slower onset. They are 
rarely used alone to induce remission in PV. 
 
After disease control is achieved there follows a consolidation phase during which drug 
doses used to induce disease control are continued. The end of this consolidation phase is 
defined arbitrarily as being reached when 80% of lesions have healed, both mucosa and 
skin, and there have been no new lesions for at least 2 weeks.47 This phase may be 
relatively short, but could be considerably longer if there is extensive cutaneous ulceration. 
Healing of oral ulceration tends to take longer than that for skin, with the oral cavity often the 
last site to clear in those with mucocutaneous PV. The end of the consolidation phase is the 
point at which most clinicians would begin to taper treatment, usually the corticosteroid dose. 
Premature tapering of corticosteroids, before disease control is established and 
consolidated, is not recommended.  
 
Remission maintenance: after induction there follows a maintenance phase during which 
treatment is gradually reduced (see section 12), in order to minimize side-effects, to the 
minimum required for disease control. The ultimate goal of treatment should be to maintain 
remission on 10 mg prednisolone daily or less, with 10 mg being the dose designated 
arbitrarily as ‘minimal therapy’ by international consensus.47 Occasional blisters are 
acceptable and indicate that the patient is not being over treated. PV is a chronic disease, 
and in one study, 36% of patients required at least 10 years of treatment.51 
 
 
Systemic corticosteroids are the most important element of remission induction and 
consolidation. In general, adjuvant drugs are slower in onset than corticosteroids. Their main 
role is in remission maintenance. Adjuvant drugs are combined commonly with 
corticosteroids with the aim of increasing efficacy and reducing maintenance corticosteroid 
doses and subsequent corticosteroid side effects. Although mortality and complete remission 
rates have improved since the introduction of adjuvant drugs, this is in comparison with 
historical controls. Until 2017, Tthere had beenare no prospective, high-quality controlled 
studies that demonstrated conclusively the presumed benefits of adjuvant drugs in PV.52 
Therefore, some authorities do nothave not used adjuvant drugs unless there are were 
contraindications or side effects of corticosteroids, or if tapering the corticosteroids dose 
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wais associated with repeated relapses.9 However, sSome trials have demonstrated lower 
cumulative corticosteroid doses, but without a difference in primary disease outcome 
measures, for azathioprine, cyclophosphamide and mycophenolate mofetil;53-55 which we 
believe this is a clinically relevant outcome. A systematic review and meta-analysis, which 
included 10 trials and pooled adjuncts together, concluded that they were not beneficial for 
achieving remission but collectively decreased risk of relapse by 29%.55 Despite thise 
sparsity of evidence, it wais commonly believed that adjuvant drugs weare likely to be 
beneficial, as proven in other areas of autoimmunity, and most centres use them as standard 
practice. In 2017, the first RCT conclusively demonstrating the benefit of an adjuvant drug 
was published: rituximab combined with short-term prednisolone showed superior efficacy 
compared to prednisolone alone, with rates of complete remission of PV, off all treatment, of 
89% compared with 28% at 2 years.  
 
 
An overview of PV management, with the aim of providing a brief reference for the clinical 





 Oral prednisolone – optimal dose not established but suggest start 
with prednisolone 1 mg/kg/day (or equivalent) in most cases, 0.5-1 
mg/kg in milder cases. 
 Increase in 50-100% increments every 5-7 days if blistering continues 
(see below* for guidance on maximum dose) 
 Consider pulsed intravenous corticosteroids if >1 mg/kg oral 
prednisolone required, or as initial treatment in severe disease 
followed by 1 mg/kg/day oral prednisolone. 
 Taper dose once remission induced and maintained, with absence of 
new blisters and healing of the majority of lesions (skin and mucosal). 
Aim to reduce to 10 mg daily or less. 
 Assess risk of osteoporosis immediately 
 Effective in all stages of disease, including remission induction 
 
Combine corticosteroids with an adjuvant immunosuppressant  
 
 Azathioprine 2 to 3 mg/kg/day (if TPMT normal) 
 Mycophenolate mofetil 2 to 3 g/day 
 Rituximab** (RA protocol, 1 g x2 infusions, 2 weeks apart) 
 
More important for remission maintenance than induction, due to delayed 
onset 
Good skin and oral care is essential. 
Second-line 
therapy 
Consider switching to alternate corticosteroid sparing agent if treatment 
failure with first-line adjuvant drug* (azathioprine, or mycophenolate mofetil or 
rituximab) or mycophenolic acid 720 to 1080 mg twice daily if GI symptoms 
from mycophenolate mofetil. 
Third-line 
therapy 
Consider choice of additional treatment options based on assessment of 
individual patient need and consensus of MDT.  
Options include: 
• Rituximab (RA protocol, 1 g x2 infusions, 2 weeks apart) 




• Intravenous immunoglobulin (IVIG) 
• Cyclophosphamide  
• Methotrexate 
• Plasmapheresis or plasma exchange 
• Immunoadsorption 
*Treatment failure 
Defined by international consensus47 as continued disease activity or failure to heal despite 
3 weeks of prednisolone 1.5 mg/kg/day, or equivalent, or any of the following, given for 12 
weeks:  
 azathioprine 2.5 mg/kg/day (assuming normal TPMT) 
 mycophenolate mofetil 1.5 g twice daily 
 cyclophosphamide 2 mg/kg/day 
 methotrexate 20 mg/week 
**Rituximab is currently approved by NHS England as a third-line treatment for pemphigus. 
Regulatory authorities in many other countries have not yet approved rituximab as a first-
line treatment.  
Abbreviations: TPMT, thiopurine methyl transferase; GI, gastrointestinal; MDT, 
multidisciplinary team; RA, rheumatoid arthritis. 
 
Table 1: An overview of the management of pemphigus vulgaris 
 
Treatment withdrawal is a realistic aim, with one study reporting rates of complete 
remission off-therapy of 38%, 50% and 75% achieved in 3, 5 and 10 years from diagnosis, 
respectively.56 Another study reported 59% of patients were off treatment after a mean 
treatment duration of 3 years and this outcome was not associated with initial disease 
severity.57 However, withdrawal of treatment should be cautious and not done prematurely; 
relapse rates are high initially, with 47% of successfully treated patients relapsing in one trial 
when treatment was stopped after 1 year.58 
 
 
12.0 ORAL CORTICOSTEROIDS (Strength of recommendation B, Level of evidence1+; 
see Appendix 1) 
 
Systemic corticosteroids are the best established therapy for the management of PV. Their 
introduction in the early 1950s resulted in a dramatic fall in mortality to an average of 30%,9 
with complete remission rates off-therapy of 13% to 20%.9,59 Outcomes have continued to 
improve and recent studies have shown that the rate of complete remission on low-dose 
corticosteroids (prednisolone 10 mg/day or less) is 52% to 76% at 1 year with very few 
deaths.53,54,60,61 
 
Clinical improvement may be seen within days of starting corticosteroids and on average, 
cessation of blistering takes 2 to 3 weeks50,53,61-64 whilst full healing may take 3 to 8 
weeks.50,61,65 IIF titres fall with corticosteroid treatment but lag behind clinical improvement.66 
 
The optimum corticosteroid dosing schedule is not known and dosing schedules are largely 
empirical and based on practical experience. Early studies advocated high doses, e.g. initial 
doses of 120 to 400 mg/day prednisolone.62,65 However, corticosteroid side effects were 
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common and dose-related67,68 with one study estimating that up to 77% of deaths were 
corticosteroid-related.67 Therefore, a more moderate approach to corticosteroid therapy has 
been advocated. However, only one RCT has compared dosing schedules; initial therapy 
with low-dose prednisolone (30 to 60 mg/day) was compared with high-dose prednisolone 
(120 to 180 mg/day) in patients with severe pemphigus (19 with PV, three with PF) affecting 
more than 50% of their body surface. There was no significant difference in the duration to 
achieve initial disease control nor in relapse rates at 5 years, and there were no deaths.63 
However, it should be noted that the dose tapered more rapidly in the high-dose arm so that 
on average, by week 7 and thereafter, the daily corticosteroid dose was lower in the ‘high-
dose’ arm. In contrast, a retrospective study showed benefit with higher corticosteroid doses: 
treatment with prednisolone 1.5 mg/kg led to significantly shorter times to achieve initial 
disease control and remission compared with prednisolone 40 mg on alternate days 
combined with azathioprine, although there were fewer side effects in the low-dose arm.60 
 
It is common practice worldwide to initiate treatment at 1 to 2 mg/kg prednisolone or 
equivalent51,53,54,61,69-73 with a majority of clinicians experienced in managing PV choosing 1 
mg/kg.69 However, milder cases may be treated with more conservative corticosteroid doses 
e.g. 0.5 to 1 mg/kg; tailored dosing according to disease severity is well established 9,65 and 
appropriate,74 with no evidence to indicate that long-term outcomes are influenced by the 
intensity of initial treatment.57,74 
 
If there is no response within 5 to 7 days, it is suggested that the dose should be increased 
in 50% to 100% increments until disease control is achieved, i.e. no new lesions and the 
onset of healing in pre-existing ones.9,61,65,71,75 If prednisolone doses above 1 mg/kg/day are 
required, pulsed intravenous corticosteroids should be considered. Treatment failure for oral 
corticosteroids has been defined by international consensus as failure to achieve disease 
control despite 3 weeks of prednisolone 1.5mg/kg/day or equivalent.47 
 
Once remission is induced and maintained with healing of the majority of lesions, both skin 
and oral, the dose of corticosteroids can be tapered cautiously. This includes assessing oral 
lesions which are often the last site to heal. The mouth and other mucosal sites must be 
examined in addition to the skin. Tapering before disease control is established and 
consolidated is not recommended. There is no established tapering schedule and those 
published in clinical trials vary widely,53,54,58,61,63,71,72,75-79 with the dose by week 12 varying 
from 5 mg75 to 60 mg daily.79 The average tapering rate across these trials was 6 mg per 
week in the first 3 months. 
 
A 50% reduction every 2 weeks has been suggested.9 The GDG consensus is to initially 
reduce the daily dose by 5 to 10 mg of prednisolone every 2 weeks down to 20 mg daily, 
then 2.5 mg every 2-4 weeks down to 10 mg daily and thereafter slowly reduce in 
increments of 1 mg. Prednisolone doses of 10 mg or less should be the aim of treatment, 
defined by international consensus as minimal therapy in PV.47 
 
Relapses in the short-term can be managed by increasing the corticosteroid dose although 
there is no consensus on the optimum way to manage relapses. They are often milder than 
initial disease presentation and are managed typically with lower corticosteroid doses. 
Various approaches to managing relapses have been suggested including reverting to the 
previous corticosteroid dose at which there was disease control;80 doubling the corticosteroid 
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dose,61,63,72 with 50% incremental increases thereafter until disease control;61 increasing to 
prednisolone 40 mg/day, or if already greater than this, to the previous dose at which 
disease control was achieved;71 increasing prednisolone dose by 10 to 20 mg/day.50,81 
Relapses that are more severe should be treated with corticosteroid doses as described for 
the initial presentation. At the time of relapse, in addition to increasing corticosteroid dose, 
long-term management should also be considered as relapses may recur when the 
corticosteroid doses are tapered again. It may be appropriate to add an adjuvant drug, 
increase the dose of an existing adjuvant or switch to an alternative, if the current adjuvant 
drug has been given at sufficient dose for at least 3 months (see table 1). 
 
It is strongly recommended that guidelines for the prevention of corticosteroid-induced 
osteoporosis are followed.30,82 A prednisolone dose of 7.5mg or more for 3 months or longer 
is considered a risk factor in those aged under 40 and any dose for those aged over 40.82 
Thus, all PV patients are at risk, assuming they are likely to exceed these limits, and bone 
health should be considered immediately upon commencing treatment because the rate of 
bone loss is most marked in the first 6 months of treatment.83 
 
Summary 
Systemic corticosteroids are a well-established and very effective treatment for PV. They 
should be used as first-line therapy.  
 
 
13.0 PULSED INTRAVENOUS CORTICOSTEROIDS (Strength of recommendation D 
(GPP), Level of evidence 4) 
 
This refers to the intermittent administration of high doses of corticosteroids, usually 
intravenous methylprednisolone (10 to 20 mg/kg or 250 to 1000 mg) or equivalent doses of 
dexamethasone given on up to 5 consecutive days.84 Generally, pulsed corticosteroids are 
given intravenously but can be delivered orally.85 The theoretical aims of ‘pulsing’ are to 
achieve more rapid and effective disease control compared with conventional oral dosing, 
thus allowing a reduction in long-term maintenance of corticosteroid doses and corticosteroid 
side effects. These theoretical benefits have not been demonstrated conclusively. In a well-
designed, double-blind RCT, monthly oral dexamethasone pulses were of no additional 
benefit and were associated with more adverse effects compared with conventional oral 
corticosteroids and azathioprine.76 However, this study was limited by small numbers (20 
patients, eleven and nine in each arm) and a relatively short follow-up (1 year). One small, 
retrospective case-controlled study concluded that pulsed intravenous methylprednisolone 
(one course of 250 to 1000 mg/day for 2 to 5 days in eight cases; two courses in one case) 
resulted in increased complete remission rates (44% vs. 0%) and lower mean maintenance 
oral corticosteroid doses in nine patients with recalcitrant PV compared with six controls.86 In 
terms of the rapidity of disease control, a retrospective case series reported signs of 
improvement within a week of pulsed methylprednisolone in all 12 patients87 but similar 
responses have been reported with oral corticosteroids. 
 
Summary 
There is no evidence that pulsed corticosteroids are superior to conventional oral 
corticosteroids for maintenance of most cases of PV. However, short-term pulsed 
corticosteroids could be considered in severe or recalcitrant PV to induce remission, 
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particularly if there has been no response to high oral doses. There is no good evidence to 
support their use in this situation but the personal experience of the GDG is that pulsing is 
very useful for rapid disease control in patients with severe disease. 
 
 
14.0 ADJUVANT DRUGS 
 
14.1 Azathioprine (Strength of recommendation B, Level of evidence 1+) 
 
a. Introduction 
Azathioprine is a commonly prescribed adjuvant drug in PV and was first used successfully 
in 1969 by Krakowski et al.88 Numerous small case series have reported a corticosteroid-
sparing effect.89-92 The complete remission rates of 28% to 45% exceed those seen in 
historical controls treated with corticosteroids alone.9,59,91 Mortality rates of 1.4% to 7% are 
lower than those seen in historical controls treated with corticosteroids alone.9,10,59,91 
 
b. Azathioprine as a single agent 
In three cases, azathioprine was used successfully as a monotherapy to induce and 
maintain clinical remission with a fall in antibody titre.90,93 However, there is a latent period of 
at least 6 weeks before the effects of azathioprine are seen89-91,93 and its use as a 
monotherapy to induce remission should therefore be reserved for mild cases only, if a delay 
in achieving disease control can be tolerated. 
 
c. Comparison with oral corticosteroids 
The role of azathioprine as a corticosteroid-sparing drug has been demonstrated in a 
number of small studies. Chaidemenos et al. compared high-dose prednisolone (1.5 
mg/kg/day) (n=17) with low-dose prednisolone (40 mg on alternate days) plus azathioprine 
100 mg/day (n=19) in a retrospective comparison.60 Both regimens were effective. Analysis 
of the 30 responders showed that the high-dose prednisolone group achieved a faster 
remission with greater side effects. The combination group had a significantly lower total 
prednisolone usage but a longer time until complete or partial remission. This was not an 
intention-to-treat analysis and the study was not powered adequately. In a retrospective 
study, described in section 14.3b, the time to remission and complete remission off-
treatment showed no significant difference when adding azathioprine (100 mg/day) to 
prednisolone (100 mg/day starting dose).94 In a large, unblinded RCT described in section 
18.1, patients randomized to the prednisolone plus azathioprine arm (n=30) had required 
lower cumulative corticosteroid doses at 1 year than those treated with prednisolone alone 
(n=30), although efficacy was similar in these two arms.53 In a subsequent study, the same 
authors performed a double-blind RCT comparing prednisolone (initial dose 2 mg/kg/day; 
n=28) plus placebo with prednisolone plus azathioprine (2.5 mg/kg/day; n=28) over 12 
months.95 Disease severity was measured using the Pemphigus Vulgaris Disease activity 
Index (PVDAI) and included an intention-to–treat analysis. No significant difference was 
seen in the mean PVDAI scores nor corticosteroid doses between the two groups over the 
12 months. However, subgroup analyses revealed differences in the two arms towards the 
end of the trial: in the final 3 months there were significant differences in the PVDAI, mean 
daily and cumulative prednisolone dose, favouring prednisolone plus azathioprine. The 
mean PVDAI of the prednisolone-only group was 2.41 and the prednisolone plus 




d. Comparison with other adjuvant drugs 
Trials comparing azathioprine with mycophenolate mofetil and cyclophosphamide are 
described in section 18. In summary, two trials have compared azathioprine with 
mycophenolate mofetil53,71 and there is evidence to suggest azathioprine has a superior 
corticosteroid-sparing effect.52 There is also some evidence that azathioprine may be less 
effective at achieving disease control.52,71 One retrospective study suggested azathioprine 
might be less effective than oral cyclophosphamide.94 Three trials have compared 
azathioprine with pulsed cyclophosphamide regimens: one RCT showed no significant 
differences;70 a non-randomized trial favoured pulsed cyclophosphamide which showed a 
lower cumulative corticosteroid dose although efficacy was similar;.72 a single-centre RCT 
showed lower cumulative corticosteroid doses in the azathioprine arm compared with the 
pulsed cyclophosphamide arm which did not reach significance in the authors’ analysis53 but 
was considered significant in an independent Cochrane review.52 
 
Summary 
Azathioprine is a well-established choice as an adjuvant drug for the management of 
pemphigus. A reasonable duration of treatment is needed to test efficacy and treatment 
failure should only be determined after at least 3 months at a dose of 2.5 mg/kg in patients 
with normal TPMT levels.47 Although there remains a lack of high-quality prospective 
randomized trials there is some evidence to suggest that the co-administration of 
azathioprine reduces the cumulative corticosteroid dose and has a superior corticosteroid-
sparing effect compared to mycophenolate mofetil. 
 
14.2 Mycophenolate mofetil (Strength of recommendation B, Level of evidence 1+) 
a. Introduction 
Mycophenolate mofetil is often used as a first-line adjuvant to corticosteroid agents. Total 
daily doses of 2 to 3 g are given typically in two divided doses with prednisolone, i.e. 1 to 1.5 
g twice daily. In patients who experience gastrointestinal side effects, mycophenolic acid can 
be given as an alternative, with the approximate equivalent doses being 720 to 1080 mg 
twice daily.  
 
Several small, unblinded trials have suggested that mycophenolate mofetil is beneficial in 
pemphigus treatment. In a series of 12 patients who had relapsed on corticosteroids plus 
azathioprine, 11 improved on mycophenolate mofetil (2 g/day) and prednisolone (2 mg/kg), 
allowing a reduction in the prednisolone dose to 5 mg/day or less during the follow-up of 1 
year. The patients responded rapidly, with a fall in IIF titres, and were free of lesions within 8 
weeks of initiating mycophenolate mofetil.96 However, based on nine patients, Nousariet al. 
commented that higher doses of mycophenolate mofetil (2.5 to 3 g/day) were often required 
to induce remission in PV and at least 8 weeks of treatment was necessary before clinical 
and immunological improvement was observed.97 There have been more than 30 case 
series since these. Examples of the number of patients achieving disease control in 
previously refractory PV patients then treated with mycophenolate mofetil as a corticosteroid 
sparing agent include 71% (22/31),98 73% (8/11),99 and 78% (14/18).100 Few adverse effects 
were reported. 
 
b. Comparison with oral corticosteroids 
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In the study described in section 18.1, 30 PV patients were given prednisolone alone (initial 
dose 2 mg/kg) and in another 30 it was combined with mycophenolate mofetil (1g twice 
daily) in this single-centre unblinded RCT.53 There were no significant differences in efficacy 
in these two arms. The cumulative corticosteroid dose in the mycophenolate mofetil arm was 
lower but did not reach statistical significance.52 
 
In an unblinded RCT,61 47 patients (36 PV, 11 PF) were allocated randomly to receive 
methylprednisolone alone vs methylprednisolone (initially 1 mg/kg prednisolone equivalent) 
and mycophenolate mofetil (1.5 g twice daily). Disease activity was scored according to the 
number of lesions present. The authors reported no difference in the time to achieve disease 
control, induction of partial and complete remissions on or off minimal therapy, or the total 
amount of corticosteroids administered. There was no difference in the frequency of relapses 
or the development of side-effects and complications.61 
 
There has been one double–blinded, placebo-controlled RCT.54 In this multicentre study, 
94/96 randomized patients were treated and 75 completed the study. Patients were 
allocated to either prednisone 1-2 mg/day (initial dose) plus placebo (n=37), prednisone plus 
mycophenolate mofetil 2 g/day (n=22) or prednisone plus mycophenolate mofetil 3 g/day 
(n=37). The primary outcome measure was the proportion of patients in each arm 
responding to treatment as determined by an absence of new or persistent lesions and a 
prednisone dose of ≤ 10 mg daily dose from weeks 48 to 52. While the authors found no 
significant difference in the primary endpoints, the time to initial response was faster and the 
time to a sustained response was 12 weeks shorter in both mycophenolate mofetil-treated 
arms. In addition, the cumulative corticosteroid dose taken over weeks 12 to 52 of the study 
was significantly lower in the combined mycophenolate mofetil arm compared to the placebo 
arm (P=0.028). Efficacy was similar in both mycophenolate mofetil arms but infectious 
adverse events were higher in those taking 3 g daily. In both these arms infections were 
commoner than in the placebo arm.54 
 
c. Comparison with other adjuvant drugs 
Studies comparing mycophenolate mofetil with azathioprine and cyclophosphamide are 
described in section 18. In summary, there is evidence that mycophenolate mofetil has an 
inferior corticosteroid-sparing effect compared with azathioprine52,53,71 but may be more 
effective at achieving disease control.52,71 Adverse events were not significantly different in 
these two studies but one did show fewer grade 3 and 4 adverse events with mycophenolate 




On the basis of current evidence, there is evidence that mycophenolate mofetil has a 
corticosteroid-sparing effect. It could be considered as an alternative to azathioprine in 
patients unresponsive to treatment or where co-morbidities/baseline investigations preclude 
azathioprine. It has a more favourable side-effect profile than azathioprine and is well 
tolerated. Treatment failure has been defined by international consensus as failure to 
respond to 3 g daily for 3 months.47 
 





Rituximab is a chimeric murine-human monoclonal antibody of immunoglobulin G1 (IgG1) 
sub-class, directed against the B lymphocyte-specific antigen CD20,101 expressed by early B 
cells in the bone marrow, autoantigen-specific B cells, memory B cells and mature B cells. 
Following treatment with rituximab there is rapid and sustained depletion of circulating and 
tissue-based B cells that is maintained for at least 6 to 12 months. Recent data suggest that 
rituximab may also affect T cell function and modulate autoreactive T cells and production of 
T cell cytokines.102 
 
b. Efficacy 
An unblinded RCT of 90 newly diagnosed and treatment-naïve patients with moderate and 
severe PV (n=74) and PF (N=16) were treated with rituximab (1g days 0 and 14 and 0.5g at 
12 and 18 months) in combination with short-term prednisolone (0.5-1 mg/kg for 3-6 months) 
compared with prednisolone alone (1-1.5 mg/kg for 12-18 months).45 There was a significant 
difference in primary outcome: 89% of patients in the rituximab arm were in complete 
remission off all treatment at 2 years compared with 34% of patients treated with 
prednisolone alone (p<0.0001). The rates were 89% vs 28% in those with PV (p<0.0001). 
There were fewer severe adverse events in the rituximab treated patients, which probably 
reflects the fact that prednisolone doses were higher and more prolonged in those treated 
with prednisolone alone. The lack of blinding is a flaw of this trial, and in particular the risk of 
withdrawal bias as drop-out rates were higher in the prednisolone only arm. However, re-
analysis assuming all withdrawals in the prednisolone-only arm went on to achieve remission 
off treatment still leads to a highly significant result. Nevertheless, the guideline group felt it 
appropriate to downgrade the recommendation rating to a B based on this single unblinded 
RCT. 
 
Whilst there are currently no double-blind RCTs of the use of rituximab in the treatment of 
pemphigus, m OtherPrevious studies of rituximab have considered its largely used it in 
patients resistant to other therapies: multiple case series (reviewed in Ahmed et al. and 
Wang et al.)103,104 suggest that it it is of utility in the treatment of PV, PF and paraneoplastic 
pemphigus with rates of remission in refractory disease of up to 86% following a single cycle 
of treatment.105 In a meta-analysis of 578 patients with pemphigus (496 PV), remission was 
achieved in 76% of patients following a single cycle of rituximab, and 39% were able to 
come off adjuvant treatments.104 In this study the mean time to disease control and 
remission was 1.1 and 5.8 months, respectively. Relapse occurred in 40% after an average 
duration of 14.5 months. Similar data is reported in an analysis of 451 PV patients from case 
series: remission was achieved in 74% to 87% after a single cycle (16% to 58% remained on 
other therapies, 27% to 58% off adjuvant treatments).103 They reported clinical responses 
within 6 weeks and a relapse rate of up to 65% occurring 13 to 17 months after rituximab. 
 
Whilst most studies to date have employed rituximab in patients resistant to other therapies 
in some centres it has been used as a first-line intervention in small numbers of 
patients.Craythorne, 2011 #138;Cho, 2014 #5459 In a single case, rituximab was used as a 
sole agent and complete healing had been achieved 6 weeks after starting treatment.106 
 
c. Dose 
Initial studies employed a dosing regimen derived from the treatment of lymphoma patients, 
using four weekly infusions of 375 mg/m2.105 A comparison of repeated weekly treatments of 
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375 mg/m2 suggested that pemphigus patients who received three or more infusions 
demonstrated more rapid complete remission of disease compared with those who only 
received one or two infusions (149 vs. 443 days) and lower levels of relapse (0% vs. 
67%).107 
 
More recently, an alternative regimen has been introduced, based on that employed in the 
treatment of rheumatoid arthritis (RA). Two infusions of 1 g rituximab, 2 weeks apart, has 
now been shown to be effective in retrospective108,109 and prospective45,110 studies. Modified 
protocols have been used, but data suggests the ‘low dose’ RA protocol (2 x 0.5 g infusions) 
has a lower response rate and shorter time to relapse than the standard RA protocol.111 
 
Comparison of the standard RA and lymphoma protocols have failed to show consistent 
superiority of either one. Two studies reported no significant differences,104,111 although there 
was a trend to better outcomes in the lymphoma protocol-treated patients in the study by 
Wang et al.104 In their analysis, Ahmed at al. showed significantly better clinical responses in 
the RA protocol-treated patients but with higher relapse rates (non-significant). In terms of 
cost, the RA protocol is less expensive, both in terms of drug cost and the associated 
expense of requiring two rather than four intravenous infusions. Lower–dose treatment (500 
mg/twice weekly) has been studied and reported to be effective112,113 though this approach, 
may be associated with poorer response and increased rates of relapse.111,114 Lower-dose 
rituximab (500 mg) has been used to control relapse following successful treatment with a 
standard 1 g x 2 induction regimen.115 
 
In a single report of resistant oral pemphigus rituximab has been used intralesionally.116 
 
d. Combination with other therapies 
Whilst rituximab has been used as a first-line drug either alone or with corticosteroids by 
several groups,Ahmed, 2016 #5552;Ingen-Housz-Oro, 2015 #5803;Cho, 2014 
#5459;Craythorne, 2011 #138 further studies to define the risks and benefits of this 
approach are required before it can be recommended as routine management. In general, 
rituximab has been used as part of combination therapy including systemic corticosteroids 
together with cytotoxic immunosuppression, or as an adjunct to treatment with IVIG117 or 
immunoabsorption.118-120 Of 372 PV patients who received rituximab reported in the study by 
Ahmed et al., 79% to 97% were treated concomitantly with adjuvant corticosteroids and/or 
immunosuppressants (59% to 69% with both).103One Two studies havey employed rituximab 
together with prednisolone alone: one study ofin 42 patients to good effect.121 and a RCT 
with 46 newly diagnosed patients (38 PV) resulting in  complete remission off treatment in 
89% of patients.45 At present, there is insufficient comparative data to indicate which of these 
approaches is preferable, either from the perspective of efficacy or adverse effects.  
 
Adjuvant systemic immunosuppressive drugs can be continued with concomitant use of 
rituximab but dose reduction should be considered to decrease the risk of infections and 
other adverse effects related to immunosuppression. 
 
e. Novel anti-CD20 agents 
A number of novel anti B-cell antibodies are currently in development,122 though to date only 
one has been reported to have been used in a patient with pemphigus. Veltuzumab (a 
humanised anti-CD20 antibody) was used as two subcutaneous injections 2 weeks apart in 
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a patient with severe pemphigus that was refractory to conventional immunosuppression and 
several cycles of rituximab.123 Complete remission resulted and was sustained for 2 years, at 
which point the patient was retreated, again with induction of remission. Whilst rituximab 
resistance is rare, such novel agents will undoubtedly be of benefit in some patients and 
may also be more convenient as a result of the subcutaneous route of administration.   
 
Summary 
The superior efficacy of rituximab and short-term corticosteroids compared to corticosteroids 
alone has been demonstrated in a single unblended RCT of newly diagnosed patients with 
pemphigus. There is also evidence that rRituximab is an effective treatment in treatment-
resistant disease and in most of these cases has been given in combination with standard 
immunosuppression. Rituximab is effective for all forms of pemphigus. and in most cases 
has been given in combination with standard immunosuppression  in treatment-resistant 
cases. Because of its long-lasting effect, cost and the associated risk of infection, currently 
its use should be reserved for those patients intolerant of or with disease refractory to 
conventional corticosteroids together with adjuvant immunosuppression. The 2 x 1 g RA 





Cyclophosphamide treatment regimens in PV vary from daily oral administration to fortnightly 
or monthly pulses, or a combination of these.124 Large, comparative trials examining differing 
doses and regimens are lacking in PV. However, it is interesting to note that studies 
analysing pulsed intravenous and daily oral cyclophosphamide therapies in the treatment of 
vasculitis suggest equal efficacy, but with a lower cumulative dose and rate of complications 
for pulsed treatment125,126 though the risk of relapse may be higher.126,127 Guidelines 
produced for the treatment of ANCA-associated vasculitis also recommend discontinuation 
of cyclophosphamide, both oral and intravenous, after 3-6 months with transfer to an 
alternative maintenance therapy, azathioprine or methotrexate, because of the risk of 
haemorrhagic cystitis, cancer and infertility associated with prolonged exposure to 
cyclophosphamide. The recommended total duration of cyclophosphamide treatment in this 
context is up to a maximum of 6 months.128 
 
b. Oral cyclophosphamide (Strength of recommendation D, Level of evidence 3) 
Early studies reported corticosteroid-sparing effects of cyclophosphamide at doses of 50 to 
200 mg/day in case series of up to six patients.129-133 Prolonged remission with cessation of 
all therapy was observed in some cases.130 In a retrospective case series including 20 
patients with PV who had failed or were intolerant to azathioprine or mycophenolate mofetil, 
or had severe PV, cyclophosphamide 2 to 2.5 mg/kg with prednisolone, initially at 1 
mg/kg/day, led to remission on minimal prednisolone doses (less than 12.5 mg/day) in 85% 
of patients.134 A larger retrospective study included 51 patients treated with 
cyclophosphamide 100 mg/daily (1.1 to 1.5 mg/kg) and prednisolone 100 mg/daily (1.1 to 1.5 
mg/kg) compared with prednisolone alone (n=20) or combined with azathioprine (n=16) or 
ciclosporin (n=14). The time to clinical and immunological remission was significantly shorter 
in the cyclophosphamide arm, with lower cumulative corticosteroid doses, suggesting 
cyclophosphamide is more effective than prednisolone alone and is superior to azathioprine 
and ciclosporin.94 However, in an earlier study superiority was not demonstrated: the efficacy 
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of prednisolone (40 mg/day) alone was compared with prednisolone/cyclophosphamide (100 
mg) and prednisolone/ciclosporin (5 mg/kg) in 28 patients with oral pemphigus.27 There was 
no significant difference in the duration to achieve remission or in relapse rates between the 
three groups but cyclophosphamide and ciclosporin were given for a brief period of only 2 to 
3 months.27 Treatment failure for oral cyclophosphamide has been defined by international 




Oral cyclophosphamide 1 to 2 mg/kg could be considered as an alternative to azathioprine 
or mycophenolate mofetil. Due to concerns about its toxicity, it is best reserved for patients 
with recalcitrant or severe PV. 
 
c. Intravenous cyclophosphamide (Strength of recommendation B, Level of evidence 
2+) 
i. Pulsed intravenous cyclophosphamide with dexamethasone or 
methylprednisolone 
This refers to the intermittent administration of high doses of intravenous corticosteroids 
and cyclophosphamide, usually three daily doses of dexamethasone (100 mg) or 
methylprednisolone (500 to 1000 mg) and a single dose of cyclophosphamide (500 mg) 
given monthly. Doses and frequency are arbitrary.  
 
Dexamethasone–cyclophosphamide pulse (DCP) therapy for PV, first described in 1984 
by Pasricha et al.,135 is widely used in India for all types of pemphigus. The originally 
described regimen comprises four phases: phase 1; monthly intravenous 
dexamethasone 100 mg on three consecutive days with 500 mg intravenous 
cyclophosphamide on day 2. Low-dose daily oral cyclophosphamide (50 mg) is 
administered between pulses. Pulsing is continued until clinical remission and followed 
by a consolidation phase of a further six DCP courses (phase 2). Oral cyclophosphamide 
is then continued alone (phase 3) and if there are no relapses after 1 year, all treatment 
is withdrawn (phase 4). Minor modifications have been made to the regimen, including 
extending phase 2 to 9 months, reducing phase 3 to 9 months and the addition of daily 
oral corticosteroids if needed during phase 1.136 Using the original regimen, 81% 
(346/425) of pemphigus patients were in remission and had been off all therapy for at 
least 2 years, 74% (313/425), for more than 5 years.136 Four percent of patients died 
during treatment. Using the modified regimen, 86% (106/123) pemphigus patients had 
completed treatment and had been off-therapy for at least 2 years, 50% (62/123) for 
more than 5 years. The mortality rate was 2%.  
 
Many other retrospective case series describing the encouraging results of this treatment 
approach have been published from both Indian centres137-143 and from other countries 
around the world including Iran, South Africa, the UK and Serbia.144-147 In one study, 
100% of 32 PV patients completed the regimen and were off treatment, in remission.138 
 
Advocates of the DCP regimen claim relative freedom from corticosteroid side effects but 
20% to 85% of menstruating females developed amenorrhoea;145,147-149 azoospermia in 
men was also noted. Haemorrhagic cystitis occurred in 0.6%149 and pituitary-adrenal 




ii. DCP regimen compared with oral corticosteroids 
DCP therapy has not been tested rigorously against other treatment protocols in 
controlled trials but one study has compared the 6% mortality achieved in 50 patients (45 
PV) on DCP therapy with an estimated 25% to 30% mortality in historical cohorts on 
conventional corticosteroid therapy at the same institute.137 More recent studies also 
indicate an advantage of combining pulsed cyclophosphamide with conventional 
corticosteroids compared with corticosteroids alone; neither used DCP therapy. In a 
controlled, open-label study, described in section 18.1, the addition of intravenous pulsed 
cyclophosphamide 1g monthly for 6 months, then every 2 months, to conventional oral 
prednisolone resulted in significantly lower cumulative corticosteroid dose at 1 year.53 
Similarly, in a randomized, prospective unblinded trial, 60 PV patients were randomized 
to receive prednisolone 1 mg/kg/day with or without monthly intravenous 
cyclophosphamide 15 mg/kg for 1 year. There were no significant differences in the two 
treatment arms but many outcomes tended to be better in the arm which included pulsed 
cyclophosphamide, with reduced relapse rates and cumulative corticosteroid doses.58 
 
iii. DCP regimen compared with alternative pulsing protocols 
One study has compared DCP therapy with an alternative pulsing protocol: in a 
prospective, randomized open-label trial, 28 PV patients received either DCP therapy or 
conventional oral prednisolone 1.5 mg/kg plus monthly cyclophosphamide pulses 15 
mg/kg. Most efficacy parameters were similar although the time to achieve remission 
was significantly shorter in the oral prednisolone plus 15 mg/kg cyclophosphamide arm.79 
However, the period of study was 1 year only.  
 
iv. Comparison of pulsed cyclophosphamide with other adjuvant drugs 
Modified DCP regimens used in several trials have failed to demonstrate consistent 
superiority over other corticosteroid/adjuvant PV treatment regimens. Studies comparing 
pulsed cyclophosphamide with azathioprine and mycophenolate mofetil are summarised 
in section 18. In summary, three trials have compared azathioprine with pulsed 
cyclophosphamide regimens: one RCT showed no significant differences;70 a non-
randomized trial favoured pulsed cyclophosphamide which showed a lower cumulative 
corticosteroid dose although efficacy was similar;72 a single-centre RCT showed lower 
cumulative corticosteroid doses in the azathioprine arm which did not reach significance 
in the authors’ analysis but was considered significant in an independent Cochrane 
review.52 Pulsed cyclophosphamide has a superior corticosteroid-sparing effect 
compared with mycophenolate mofetil.52,53 
 
v. Dose 
The dose of intravenous cyclophosphamide most commonly reported for the treatment of 
PV is a fixed dose of 500 mg monthly but this is arbitrary and is often combined with 50 
mg/day oral cyclophosphamide. Three studies have given 15 mg/kg intravenous 
cyclophosphamide monthly combined with conventional oral corticosteroids and without 
daily oral cyclophosphamide.58,79,81 In another, a fixed dose of 1 g intravenous 
cyclophosphamide monthly was given, without daily oral cyclophosphamide, and 
combined with conventional oral corticosteroids.53 It is common practice to combine 




The dose of 15 mg/kg for an intravenous cyclophosphamide pulse is commonly used in 
the treatment of other severe autoimmune diseases. For example, in remission induction 
of ANCA-associated systemic vasculitis, pulsed intravenous cyclophosphamide 15 
mg/kg (maximum dose 1500 mg) is given initially every 2 weeks, reducing to every 3 
weeks and continued for a maximum of 6 months.128 
 
Summary 
There is some evidence that pulsed cyclophosphamide therapy may reduce cumulative 
corticosteroid dose. There is no consistent evidence that it is more effective than other 
adjuvant drugs so in view of concerns about long-term toxicity and the practical 
disadvantages of administering regular intravenous treatment, it is best reserved for 
severe or recalcitrant cases of PV. 
 
14.125 Intravenous immunoglobulin (IVIG) (Strength of Recommendation B, Level of 
Evidence 2++) 
 
Many reports have suggested the utility of IVIG in patients with PV151-154 and a recent 
double–blind, placebo controlled study in 61 patients has confirmed this in a robust way.155 
PV patients treated with a single cycle of IVIG (either 1g/kg or 2g/kg divided over 5 days) did 
significantly better, measured according to the need for additional treatment, than those 
treated with placebo and a dose-response effect was demonstrated. Clinical improvement 
was measured objectively and seen by day 8 in the higher-dose treatment arm. In addition, a 
significant fall in desmoglein antibody titres was demonstrated in both treatment groups with 
no fall in the placebo group. A placebo-controlled crossover trial of IVIG in a single patient 
also confirmed its efficacy, with significantly improved disease activity scores and lower 
indirect immunofluorescence titres and desmoglein 1 and 3 antibody levels.156  
 
In pemphigus, IVIG is generally used at high dose, typically 2g/kg in divided doses over 
several days, together with corticosteroids with or without cytotoxic immunosuppressive 
agents such as azathioprine or mycophenolate mofetil. Treatment is given at monthly 
intervals and may need to be prolonged for continued effect. Thus, multiple treatments will 
be needed if used to maintain remission. IVIG seems to act by increasing catabolism of 
pathogenic antibodies.157,158 It is generally well tolerated154 and has the attraction over other 
adjuvant therapies that it does not increase the risk of infection Intravenous immunoglobulin 
has been used to treat pemphigus in pregnancy159 and in children.160 
 
Whilst uncommon, adverse effects of IVIG do occur, including headache and aseptic 
meningitis and anaphylaxis which is a particular risk in patients who are IgA-deficient. 
 
Summary 
IVIG could be considered as maintenance treatment in patients with refractory disease 
unresponsive to other adjuvant drugs. In view of reports of a rapid action in some cases, it 
may also be used to help induce remission in patients with severe PV while slower-acting 
drugs take effect. IVIG should be considered as part of the acute management of severe or 
widespread pemphigus and patients who are at particularly high risk of infection. 
 




Methotrexate has been used as an immunomodulatory and corticosteroid-sparing agent in a 
variety of skin diseases. Studies from the late 1960s and early 1970s14,161-163 attributed high 
morbidity and mortality to methotrexate and hence it fell out of favour for its adjuvant use in 
PV. Three of four patients cited in one report died, but high doses of methotrexate had been 
used (125 to 420 mg/week) in combination with 40 to 240 mg of prednisolone a day.14 There 
have been no controlled trials evaluating the role of methotrexate in the treatment of PV.162-
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A retrospective review of 116 patients with PV revealed clinical improvement in 83% 
(96/116) when methotrexate was used in doses between 10 to 50 mg/week, in combination 
with corticosteroids. Thirteen patients did not improve, two had it discontinued for unknown 
reasons, and five died from causes unrelated to methotrexate therapy. Of the responders, 14 
patients were clear at a mean of 2.6 years (range 3 months to 18 years) after discontinuation 
of all systemic therapy.167 
 
Two retrospective studies have shown a corticosteroid-sparing effect with the use of 
methotrexate in PV. In a 25-year survey of 53 patients treated with methotrexate and 
systemic corticosteroids, there was a 50% reduction in the dose of corticosteroids168 and in 
the second study, prednisolone (mean dose prior to treatment with methotrexate 20 mg/day; 
range 3 to 40 mg) was discontinued in six of nine patients.169 
 
In 2012, a retrospective review of methotrexate use in PV reported its effectiveness in 
moderate-to-severe cases as an adjuvant to systemic corticosteroids. A pre-determined 
severity score was used by the authors, which included the number of erosions, percentage 
of body surface involved and the dose of prednisolone used. A total of 30 patients were 
identified and used methotrexate 15 mg/week. Of the 25 patients described as severe or 
moderate in the study, 84% (21/25) improved their severity score within 6 months (p = 
0.00001). Only 13% (4/25) experienced side effects. The dose of prednisolone was reduced 
(range 2.5 to 85 mg) in 23 patients (76.6%) and in 21 patients (70%) the decrease was 50% 
or more.170 
 
A retrospective review by Tran et al 171 on the adjunctive use of methotrexate in patients with 
PV has demonstrated its effectiveness as a corticosteroid-sparing agent; 23 patients with PV 
were treated with methotrexate, of which 21 (91%) experienced improvement (as measured 
by reduction in the prednisolone dose). Sixteen patients (70%) were eventually weaned off 
prednisolone completely. The mean dose of methotrexate used in this study was 18.9 
mg/week (range 15-25 mg/week).    
 
Summary 
Given the limitations of the data available, it would be difficult to recommend methotrexate 
as a first-line agent in the treatment of PV.172 Methotrexate could be considered as an 
adjuvant drug if more established drugs cannot be used or have failed. International 
consensus has defined treatment failure as persistent disease despite methotrexate 20 
mg/week for at least 12 weeks.47 
 




Dapsone has been reported to be beneficial as an adjuvant drug in several case reports of 
PV.173-177 However, in three of these cases, it was started either with or shortly after 
prednisolone and in two cases it was started after the long-standing prednisolone was 
increased to high doses. Therefore, it is difficult to be certain if dapsone had a significant role 
if any. 
 
In a case series, five of nine PV patients in the maintenance-phase of treatment and who 
had been unable to reduce their prednisone dose below 15 mg/day or more, experienced a 
mean (±SEM) drop of 67% (±7.1%) in prednisone dose after 4 months of maximal dapsone 
treatment and an 84% (±3.5%) drop in prednisone dose after 8 months of dapsone 
treatment.178 
 
There has been one double-blind, placebo-controlled RCT undertaken to look for a potential 
corticosteroid-sparing effect of dapsone. Nineteen PV patients on maintenance treatment 
with corticosteroids and/or immunosuppression were randomized to additional dapsone 
(n=9) vs. placebo (n=10). The primary outcome measure was reduction of prednisolone to 
7.5 mg daily for at least 30 days within 1 year of achieving the maximum dapsone dose (150 
to 200 mg/day). The results were based upon an intention-to-treat analysis and did not show 
a statistical difference, i.e. 56% (5/9) of dapsone group were treated successfully, three 
failed treatment and one left the study. Among the placebo group 30% (3/10) were treated 
successfully, 57% (4/7) of those that failed treatment were treated with dapsone and in 75% 
(3/4) of those it was successful. Among those that completed the dapsone trial, 73% (8/11) 
vs. 30% (3/10) placebo showed a corticosteroid-sparing effect with dapsone. However, the 
study numbers are very small and at best may only show a slight trend for a corticosteroid-
sparing effect with dapsone.77 
 
Summary 
There is weak evidence to suggest dapsone may have a corticosteroid-sparing effect. Larger 
placebo-controlled RCTs are needed. 
 
14.7.8 Tetracyclines/nicotinamide (Level of evidence 3) 
 
Tetracyclines have been used in the treatment of PV, with or without nicotinamide, in varying 
combinations. Sixteen patients were given nicotinamide 1.5 g and tetracycline 2 g daily. In 
12, no systemic corticosteroids were given and of these, three cleared and three 
improved.179,180 Of the four patients given additional prednisolone, there was clearance in 
one, partial improvement in two and no response in another.179 
 
Thirteen hospitalized patients with PV were given tetracycline 2 g daily for a month followed 
by 1 g a day for the next 4 weeks in combination with oral prednisolone. They had a faster 
response rate and required lower doses of prednisolone compared with seven historical 
corticosteroid-treated controls.181 
 
Two studies using minocycline 50 to 200 mg/day as an adjuvant drug reported improvement 





Tetracyclines, with or without nicotinamide, are not widely used for the treatment of PV and 
evidence of their corticosteroid-sparing role is weak, but they could be considered as 
adjuvant treatment, perhaps in milder cases of PV. 
 
14.9. Sulfasalazine and pentoxifylline (Level of evidence 1-2-) 
A double-blind, placebo-controlled clinical trial in 64 PV patients was carried out to ascertain 
the value of sulfasalazine (SSZ) and pentoxifylline (PTX) as an adjuvant therapy for PV. 
Patients were not randomized. The drugs were chosen as low-cost, anti-tumour necrosis 
factor agents. All patients received standard pulsed therapy with intravenous corticosteroid 
(500 mg on 5 consecutive days) and pulsed cyclophosphamide (on day 1) in a 2- to 4-
weekly cycle with oral cyclophosphamide (100 mg/day) and oral corticosteroid (60 mg/twice 
weekly) between the cycles. In addition, group 1 (n=42) were treated with oral SSZ 500 
mg/twice daily and PTX 400 mg/twice daily for 8 weeks while group 2 (n=22) received a 
placebo. The serum level of TNF-α was higher statistically in both groups of patients than in 
the healthy individuals. There was a statistically significant decrease in the serum levels of 
TNF-α in patients in group 1 compared with those in group 2 at 6 and 8 weeks. There was 
also a rapid clinical improvement in patients in group 1 compared with those in group 2.184 
 
Summary 
There is some evidence to support the use of PTX and SSZ as adjuvant therapy in the 
treatment of PV but further studies are required 
 
14.10. Chlorambucil (Level of evidence 3) 
 
Like cyclophosphamide, chlorambucil is a nitrogen mustard alkylating agent. Since the last 
guidelines were compiled, there have been no new reports of the use of chlorambucil in PV. 
The biggest series, published in 2000, involved seven patients with PV who had failed to 
respond to other corticosteroid and immunosuppressants. They were given oral chlorambucil 
4 mg/day, titrated upwards according to clinical response. There was improvement or 
remission in five patients and a corticosteroid-sparing effect was noted. A fall in IIF titres was 
reported in three of four cases.185 The lack of bladder toxicity with chlorambucil is an 
advantage compared to cyclophosphamide. 
 
Summary 
Chlorambucil could be considered as an adjuvant drug if more established options cannot be 
used but there are limited data to support its use. 
 
 
14.411 Gold (Strength of recommendation D, Level of evidence 3) 
Gold is a historical treatment, rarely used now in the treatment of PV nowadays. Most 
studies have used intramuscular gold, given as sodium aurothiomalate initially at a dose of 
50 mg/week intramuscular injection (im) if test doses were tolerated. It was used 
successfully as monotherapy in five patients with an associated fall in IIF titres.186,187 
However, it has been used more commonly as an adjuvant drug and corticosteroid-sparing 
effects are reported. Penneys et al. reported a series of patients receiving gold for up to 4 
years with 14 of 15 patients responding. Eight achieved remission off-treatment after a mean 
of 21 months, 7 achieved remission on treatment and one stopped due to side effects.188 In 
a retrospective review of 26 patients treated with gold over 10 years, a response was seen in 
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62% and complete remission off-treatment had occurred in four patients. Toxicity was seen 
in 42%. The average dose of prednisolone was reduced from 55 mg/day pre-gold to 9 
mg/day at the end of the study.189 A more recent study used gold as an adjuvant therapy in 
13 patients with prednisolone doses ranging from 7.5 to 100 mg. The addition of 50 mg im 
gold was felt to be beneficial as 7 patients went into complete remission and 4 were able to 
reduce prednisolone doses.190 
Significantly, there are also case reports implicating gold as a trigger for pemphigus. Gold 
compounds contain a thiol group which has previously been implicated in drug-induced 
pemphigus. Lo Schiavo et al. reported a convincing case of gold-induced pemphigus in a 
patient with rheumatoid arthritis, with complete resolution on withdrawal of gold.191 
Summary 
Gold is now a historical treatment in most developed healthcare systems. It could be 
considered as an alternative to more established adjuvant drugs if they cannot be used or 
are unavailable. However, the lack of randomized trial data makes the magnitude of an 
effect uncertain and there is a risk of gold acting as a disease trigger. 
 
14.6.12 Ciclosporin (Level of evidence 1-) 
There are a number of case reports suggesting that ciclosporin is a useful adjuvant with 
corticosteroid-sparing effects in PV.64,192-194 However, a small prospective single-centre RCT 
of 33 patients comparing oral methylprednisolone 1 mg/kg alone vs. methylprednisolone with 
ciclosporin 5 mg/kg found no statistically significant difference in outcome measures such as 
time to healing, complete remission rate and cumulative corticosteroid dose. More side 
effects were encountered in the ciclosporin group during a mean follow-up period of 5 
years.195 There were no deaths and 10 patients (five from each group) were in complete 
remission, off all therapy, while the others were taking an average of prednisone 2.5 
mg/day.195 Olszewska et al. reported a retrospective series of 101 patients with PV treated 
with prednisolone alone (n=20) or in combination with adjuvant immunosuppressants, 
including azathioprine (n=16), ciclosporin (n=14) and oral cyclophosphamide (n=51). 
Cyclophosphamide plus prednisolone was significantly better at inducing remission than 
prednisolone alone. Ciclosporin did not add any significant benefit. The proportion remaining 
relapse-free 5 years after discontinuation of treatment was lowest in the ciclosporin group, at 
43%, and highest in the cyclophosphamide group at 69%.94 
 
Summary 




15.0 PLASMA EXCHANGE/PLASMAPHERESIS (Strength of Recommendation D, Level 
of Evidence 3) 
 
Plasma exchange has been used for many years in the management of antibody-mediated 
autoimmune disease, including pemphigus. Thus, multiple case reports and small case 
series have reported clinical benefit, short-term falls in IIF titres and a corticosteroid-sparing 
effect of plasma exchange.196-208 In general, these were problematic patients with either 
corticosteroid side effects, poorly controlled disease on conventional therapy or life-
threatening disease. However, a randomized study of patients with newly diagnosed 
pemphigus treated with oral corticosteroids with or without additional plasma exchanges 
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failed to demonstrate any additional clinical benefit of plasma exchange. Cumulative 
corticosteroid doses and changes in IIF titre in the two groups were similar. Furthermore, 
there were four deaths from sepsis in the plasma exchange group.209 In the cases reported 
that have been treated successfully, plasma exchange has been combined with both 
corticosteroids and immunosuppressive drugs - it is thought that the latter is necessary for 
sustained clinical effect in order to prevent rebound production of autoantibodies stimulated 
by the plasma exchange.196,199,204,205,210-213 IVIG has been reported to have a similar action 
and has been used successfully in combination with plasmapheresis.214 
 
Plasma exchange is not without adverse effects as, in addition to pathogenic 
immunoglobulins, other important plasma proteins are removed such as clotting factors that 
can result in coagulation defects.215 
 
Summary 
Plasma exchange cannot be recommended as a routine treatment option in newly 
presenting patients with pemphigus but may be considered in refractory cases if combined 
with corticosteroids and immunosuppressant drugs. 
 
 
16.0 EXTRACORPOREAL PHOTOPHERESIS (Strength of Recommendation D, Level of 
Evidence 3) 
Extracorporeal photopheresis is known to have immunomodulatory effects216 and has been 
used in small numbers of patients with pemphigus;217-222 there are no RCTs. In a recent case 
series, 8 patients with pemphigus were treated with 2 to 6 cycles of extracorporeal 
photopheresis, resulting in complete remission in all but one case. Steroid doses could be 
tapered in all treated patients.223 
 
Summary 
Extracorporeal photopheresis could be considered in recalcitrant cases of PV where there 
has been failure to improve with more conventional therapy.  
 
 
17.0 IMMUNOADSORPTION (Strength of Recommendation D, Level of Evidence 3) 
 
Immunoadsorption is an extracorporeal apheresis technique in which patient serum is 
passed over a matrix that selectively adsorbs immunoglobulin. Consequently it removes 
circulating pathogenic antibodies and is widely used in transplantation medicine.224 
Immunoadsorption was first used in the management of pemphigus in 1999 and several 
case series and reports have evidenced its utility since then.225-227 Various matrices have 
been used including Staphylococcal Protein A and tryptophan.226-228 
 
Immunoadsorption has been used together with rituximab118,119 and other adjuvant 
immunosuppressive agents.120,226,227 It is effective in difficult-to-treat disease and represents 
a rational approach in the reduction of circulating pathogenic antibody levels when combined 
with treatment directed at suppressing new antibody formation such as rituximab.118 Daily 
treatment over 3 consecutive days can result in falls in desmoglein antibody levels of up to 
95%.228 As yet, however, there is no consensus on an optimal matrix or regimen and the use 
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of immunoadsorption should be reserved for the treatment of patients resistant to or 
intolerant of other approaches. 
 
Summary 
Immunoadsorption could be considered in recalcitrant cases of PV where there has been 
failure to improve with more conventional therapy.  
 
 
18.0 COMPARISONS OF SYSTEMIC ADJUVANT DRUGS 
 
18.1 Azathioprine and mycophenolate mofetil 
In an unblinded multicentre RCT, 40 patients with pemphigus (33 PV and 7 PF) were 
randomized to receive mycophenolate mofetil (1g twice daily, n=21) or azathioprine 
(2mg/kg/day, n=18), both in combination with a standardized corticosteroid regimen 
(methylprednisolone, initial dose 2mg/kg/day); they were followed-up for 2 years. There were 
no significant differences in efficacy, adverse event profile or cumulative corticosteroid dose 
between the two arms. There was a trend towards azathioprine achieving a faster clinical 
remission, although more patients achieved remission with mycophenolate mofetil 95% 
(20/21) after a mean of 91 days vs. azathioprine 72% (13/18) after a mean of 74 days, and 
there were fewer grade 3 or 4 adverse events with mycophenolate mofetil (19% vs. 33% for 
azathioprine). However, the study was small with wide confidence intervals.71 
 
In a further unblinded single-centre RCT, mycophenolate mofetil and azathioprine were 
compared as adjuvant drugs, in addition to pulsed cyclophosphamide.53 A total of 120 PV 
patients were randomized to four groups of 30 patients: prednisolone alone (initial dose 2 
mg/kg/day); prednisolone plus azathioprine (2.5 mg/kg/day for 2 months followed by 50 mg 
daily); prednisolone plus mycophenolate mofetil (2 g/day); prednisolone plus intravenous 
cyclophosphamide (1g monthly for 6 months, then 1g every 2 months). A total of 111 
patients completed the 1-year follow-up. Efficacy and adverse events were similar in all four 
arms but the cumulative corticosteroid dose was significantly higher in the prednisolone-only 
arm compared with the combined adjuvant groups. The lowest cumulative dose was in the 
azathioprine arm (azathioprine <intravenous cyclophosphamide <mycophenolate mofetil) 
and there was a significant difference between the azathioprine and mycophenolate mofetil 
arms, favouring azathioprine. 
 
In a Cochrane systematic review52 of these two studies comparing mycophenolate mofetil 
with azathioprine,53,71 the combined data showed that azathioprine had a significantly better 
corticosteroid-sparing effect, measured as cumulative corticosteroid dose. However, they 
concluded that the Beissert et al. study71 showed that mycophenolate mofetil was more 
effective than azathioprine at achieving a higher proportion of patients with disease control.52 
 
18.2 Azathioprine and oral cyclophosphamide 
A retrospective study of 101 patients included 20 treated with prednisolone alone and three 
groups treated with combinations of prednisolone and immunomodulatory drugs: 51 treated 
with cyclophosphamide 100 mg daily (1.1 to 1.5 mg/kg) 16 with azathioprine (100 mg daily 
initial dose) and 14 with ciclosporin (2.5 to 3 mg/kg/day). The time to clinical remission was 
significantly shorter in the cyclophosphamide arm compared with the other three groups. The 
cyclophosphamide group also had a lower cumulative corticosteroid dose and a shorter time 
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to immunologic remission (no detectable antibodies). This study suggests that 
cyclophosphamide plus prednisolone is more effective than prednisolone alone and is 
superior to azathioprine plus prednisolone and ciclosporin plus prednisolone.94 
 
18.3 Azathioprine and intravenous cyclophosphamide 
In a small, multicentre RCT of 22 pemphigus patients (16 PV) a regimen of oral 
methylprednisolone (initial dose 2 mg/kg) and azathioprine (2 to 2.5 mg/kg) was compared 
with a DCP regimen. The DCP regimen comprised pulses of 3 x 100 mg intravenous 
dexamethasone and 500 mg intravenous cyclophosphamide day 1, repeated every 2 to 3 
weeks initially, dropping down in frequency to every 6 weeks. Oral cyclophosphamide 50 mg 
daily was given between pulses but stopped after 6 months. Cyclophosphamide pulses were 
stopped when there was no relapse at 6 weeks from the last dose, but dexamethasone 
pulses were continued every 12 weeks. Patients were followed up for 2 years and there 
were no significant differences in either efficacy or adverse effects in the two treatment 
arms.70 
 
Another study has compared a modified DCP regimen (each course included 1000 mg 
intravenous methylprednisolone for 4 days plus 500 mg intravenous cyclophosphamide for 1 
day) with oral prednisolone (1 to 2 mg/kg initial dose) plus azathioprine (100 to 150 mg/ 
daily). Only 3 monthly pulses were given with oral cyclophosphamide 50 mg/daily and oral 
prednisolone, initially 30 mg/daily, between pulses. It was not randomized, with 72 patients 
in the pulse arm and 51 in the control arm. Most outcome measures were similar in both 
groups although at 1 year, cumulative corticosteroid doses and weight gain were significantly 
greater in the azathioprine arm suggesting superiority of the DCP regimen compared with 
oral prednisolone and azathioprine.72 
 
In the non-blind single centre RCT which recruited 120 PV patients and is described in 
section 18.1, efficacy and adverse effects were similar in the pulsed cyclophosphamide and 
azathioprine arms.53 Cumulative corticosteroid dose was lower in the azathioprine arm but it 
was not significantly different to the cyclophosphamide arm. However, a Cochrane 
systematic review of this data indicated the difference in cumulative corticosteroid dose was 
significant, favouring azathioprine as an adjuvant drug.52 
 
18.4 Intravenous cyclophosphamide and mycophenolate mofetil 
Only one study comparing cyclophosphamide pulses with mycophenolate mofetil has been 
described (see section 18.1). In this study 30 PV patients were recruited to each arm. There 
were no significant differences in efficacy or adverse events.53 Both arms showed a 
corticosteroid-sparing effect, measured as cumulative prednisolone dose, but the difference 
between the cumulative corticosteroid dose in both arms was reported by the authors as not 
significant using ANOVA. A Cochrane systematic review of this data indicated the difference 




19.0 TOPICAL THERAPY FOR THE SKIN (Level of Evidence 1-) 
 
PV is largely managed with systemic therapy. However, high-quality skin care is essential 
and adjuvant topical therapy, including topical corticosteroids, may be of additional benefit, 
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although there are no controlled studies to confirm this. Rarely, patients with mild disease, 
particularly if confined to the mucosal surfaces, can be managed on topical therapy alone. 
Huilgol et al. have reviewed topical therapy for pemphigus and pemphigoid in detail.229,230 
Topical tacrolimus ointment 0.1% in combination with systemic treatment has been reported 
to heal recalcitrant facial erosions.231 A small, randomized double-blind clinical trial (11 
patients, 62 lesions) demonstrated significant benefit of pimecrolimus 1% cream over 
placebo for the healing of cutaneous erosions. The patients were also receiving systemic 
immunosuppression.232 Other small randomized trials treating cutaneous lesions have 
suggested benefit from pilocarpine gel 4%,233 nicotinamide gel 4%234 and epidermal growth 
factor(10 µg/g) in 0.1% sulfadiazine cream.235 Scalp lesions can be particularly persistent 
and are often covered in thick crust rather than being eroded. Soaking the crust in emollient 
or oil followed by gentle washing to remove the crust allows topical corticosteroids to 
penetrate better. Avoid corticosteroid scalp preparations in an alcohol base because they 
sting; use lotions or creams instead. Nasal lesions can be managed with topical 




20.0 ORAL MANAGEMENT (Strength of recommendation D, Level of evidence 3) 
 
Oral lesions in PV are characterized by painful ulceration involving any surface of the oral 
cavity. The buccal mucosa, soft palate, lips and tongue are most frequently affected. Painful 
erosions on the gingival margins may inhibit tooth brushing resulting in an accumulation of 
plaque. This compounds the pain and inflammation. Furthermore, patients with PV have a 
worse periodontal status than seen in matched controls.236,237 
 
a. Topical corticosteroid preparations 
These are frequently used as adjunctive therapy. However as most patients are on 
concomitant systemic therapy evidence for the additional benefit of topical treatments is 
poor. Nevertheless, topical corticosteroid preparation are often used in patients with mucosal 
PV and include corticosteroid mouthwashes such as betamethasone sodium phosphate 0.5 
mg dissolved in 10 mL of water as a 2-3 minute rinse-and-spit solution 1-4 times a day, 
flixonase nasules diluted in 10 mL of water twice daily or clobetasol 0.05% ointment mixed in 
50% Orabase® twice weekly applied to localised lesions on a dried mucosa. The latter can 
be mixed together by the patient and stored in the fridge. 
 
b. Tacrolimus 
In a split-mouth,(two treatments compared when applied to one or other side of the mouth at 
the same time) randomized trial over 2 weeks (n=15) the efficacy of triamcinolone acetonide 
0.1% paste (Volon-A®) was compared to tacrolimus 0.1% ointment (Protopic®).The degree 
of mucosal involvement and pain scores were significantly reduced in both treatments 
compared with baseline but there was no difference between the treatments.238 Topical 
tacrolimus, applied twice daily for 4 weeks was beneficial in one case of recalcitrant PV 
affecting the lips.239 
 
c. Topical ciclosporin  
There are small numbers of reports indicating that topical ciclosporin is effective for the oral 
lesions of PV. A 5mL (500 mg) of oral suspension used 3 times a day for 2 months in oral 
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pemphigus (n=12) recalcitrant to conventional treatment was reported to result in significant 
improvement in both symptoms and signs of PV.240 
 
Ciclosporin mouthwash(100 mg/ml) 5mL used 3 times day was effective within 6 months in a 
patient with recalcitrant oral lesions for 20 years.241 Treatment was reduced and the patient 
was maintained on a once-daily mouthwash for 5 years. In a further three PV patients, 66% 
(2/3) patients had a clinical improvement.242 However, topical ciclosporin tastes unpleasant 
and is relatively expensive.242 
 
d. Intralesional triamcinolone 
Mignogna et al. evaluated the efficacy of perilesional/intralesional triamcinolone acetonide 
injections in oral PV in addition to conventional immunosuppressive therapy plus topical 
corticosteroid (n=16) in an open-label trial.243 In comparison to a group of patients not 
receiving injections (n=19), the perilesional/intralesional triamcinolone acetonide group 
achieved a shorter time to clinical remission (126 days vs. 153; not statistically significant) 
and obtained acceptable compliance with this treatment.  
 
e. Topical prostaglandin E2 
Topical prostaglandin E2 applied twice daily in ten patients with oral lesions in PV resulted in 
complete healing by 3 months in 30% (3/10) PV patients. These had mainly mild disease 
affecting one mucosal site. A further three patients improved as long as treatment was 
continued but relapsed within 7-10 days of stopping therapy while 4/10 did not improve. 

























Recommendations for oral treatment 
 
• Maintenance of good oral hygiene is paramount. Use of soft 
toothbrushes and mild, mint-free toothpaste may be helpful, e.g. 
paediatric formulations or Kingfisher fennel. Regular, 3-monthly 
attendance to a dental hygienist is recommended. In addition, use of an 
antiseptic mouthwash two or three time a week diluted if necessary, may 
also be helpful. Agents include 1.5% hydrogen peroxide, e.g. Peroxyl® 
mouthwash, 10 ml twice daily or 0.2% chlorhexidine digluconate 
mouthwash, e.g. Corsodyl® mouthwash, 5-10 ml twice weekly. Dilution 
of mouthwashes (50%) may be necessary to reduce discomfort. Barrier 
preparations such as Gengigel ® mouth rinse or gel or Gelclair ® are also 
helpful for pain control. 
 
• Use of an anti-inflammatory oral rinse or spray containing benzydamine 
hydrochloride, e.g. Difflam® oral rinse or spray may be helpful 
particularly before meals. Anaesthetic preparations, e.g. viscous 
lidocaine 2% gel may also be helpful.  
 
 Patients are susceptible to oral candida and therefore oral swabs or 
saliva sampling is helpful at each visit. Use of nystatin oral suspension 
four times a day for 1 week per month may be helpful.  
 
 For multiple oral erosions, mouthwashes are most practical, for 
example, soluble betamethasone sodium phosphate 0.5 mg tablet 
dissolved in 10 mL water may be used up to four times daily, holding the 
solution in the mouth for about 2 to 3 minutes and reducing the 
frequency as oral lesions improve. Flixonase nasules (400 μg) similarly 





















21.0 NURSING CARE 
 
PV has the potential to cause extensive cutaneous erosion, and in very active cases, fragility 
of normal skin (exhibited by a positive Nikolsky sign). Therefore, careful handling of the skin 
by specialist dermatology nurses, or other nursing staff familiar with caring for patients with 
skin failure, is essential. Attention to fluid balance, haemodynamic stability, 
thermoregulation, prevention of infection, prevention of further skin trauma, pain 
management, nutritional intake and psychological support is equally important in addition to 
skin care.245 
 
It is recommended that any intact bullae are decompressed by piercing. The blister roof is 
left in situ to act as a biological dressing. A daily blister chart is a useful means of mapping 
disease progress in the acute phase.246 
 
21.1 A guide to blister management: 
 
Anecdotal experience suggests that aspirating blisters causes more discomfort than piercing 
them. Table 2 summarises the management of blisters for all types of bullous disease 












1. Gently cleanse blister with antimicrobial solution, taking 
care not to rupture 
2. Pierce blister at base with a sterile needle, with the 
bevel facing up. Select a site in which the fluid will drain 
out by gravity to discourage refilling. 
3. Gently apply pressure with sterile gauze swabs to 
facilitate drainage and absorb fluid. 
4. Do not de-roof the blister. 
5. After fluid has drained, gently cleanse again with an 
antimicrobial solution. 
6. It may be necessary to apply an atraumatic non-
adherent dressing. 




















Table 2. Management of blisters 
 
The application of a bland emollient, such as 50% white soft paraffin and 50% liquid paraffin, 
is recommended to support barrier function,247 reduce transcutaneous water loss and 
encourage re-epithelialisation.248,249 This should be applied to the whole skin including 
erosions. Avoid products containing irritants and sensitizers. To reduce the shearing forces 
and pain associated with application of emollients to erosions, a 50:50 aerosolized 
preparation of white soft liquid paraffin can be used to supplement application of the 
ointment form. Emollients can be applied directly to the skin or initially to primary dressings. 
 
Potassium permanganate soaks (one Permatab® – 400 mg – in 4 litres of water, i.e. a 
1:10,000 solution) may be helpful for wet, weepy erosions. The solution should not be 
applied for longer than 15 minutes as it becomes ineffective due to oxidation. If practical, 
soaking in a bath is an effective way of treating large areas. Alternatively, it can be applied 
by soaking gauze swabs or dressing pads and applying to affected areas. The patient should 
be counselled regarding temporary skin discoloration. Nails should be covered with 
white/yellow soft paraffin to help prevent nail discoloration.250-252 
 
There is no clear evidence regarding the superiority of any particular dressing in PV, but 
those used should be non-adherent.253 The application of an emollient and dressing to 
eroded areas helps reduce fluid and protein loss, reduces the risk of secondary infection and 
assists with pain control. A soft silicone mesh dressing, such as Mepitel®, is a suitable 
primary dressing, and it can be coated (spread) with an appropriate emollient such as 50:50 
mix of liquid paraffin and white soft paraffin, or topical antimicrobial if appropriate, prior to 
applying to the skin. The secondary dressing usually needs to be absorbent, such as a soft 
silicone foam or other foam dressing, for example Mepilex® or Allevyn®.253 These dressings 
can be secured to the trunk or the limbs with soft knitted tube dressings such as Comfifast®.  
 
When dressings are removed, if they have dried onto the skin, they should be soaked off to 
minimize pain and avoid further damage.254 There is no evidence regarding the optimal 
frequency of dressing changes but one should consider the appearance of strikethrough on 
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the secondary dressing, the need to assess for evidence of infection and the stage of wound 
healing. In the acute stage, dressings should be changed daily to assess these. It may be 
appropriate in the later stages of healing to change only the secondary dressing but leave 
the primary dressing in situ, the underlying erosion left undisturbed. Further applications of 
topical agents can be placed on top of the silicon mesh primary dressing in this situation. 
Crusts should be removed to promote healing. All pemphigus patients should be nursed on 
an appropriate pressure-relieving mattress regardless of the degree of skin failure as they 
are prone to developing pressure areas by virtue of the disease.255 
 
Infection and sepsis are a significant risk and a major cause of mortality in PV so vigilance in 
detecting signs of infection is essential.256 Infection also increases the risk of scarring. Daily 
washing with an antibacterial product can decrease colonization. Dressings should be 
changed using an aseptic technique and patients with extensive erosions barrier nursed. 
Erosions showing clinical signs of infection should have bacterial and viral swabs sent. It 
may be appropriate to apply topical antimicrobials for short periods only. Systemic antibiotics 
should be used if there are local or systemic signs of infection or extending infection of the 
skin. Local policy should guide the choice of antibiotic agent. 
 
Pain control is essential, and attention needs to be paid both to acute and maintenance 
(background) analgesia with the ability to provide timely additional short-term boosts when 
needed, for example with dressing changes. The advice of a pain team may be necessary. 
 
 
22.0 PEMPHIGUS IN PREGNANCY (Level of evidence 3) 
 
This is a rare occurrence requiring close cooperation between dermatologist, obstetrician 
and neonatologist. Careful selection and monitoring of immunosuppression during 
pregnancy is required. Due to the passive transfer of maternal IgG autoantibodies across the 
placenta, the neonate may be affected by cutaneous erosions. In 2009, Kardos et al. 
published a review of 38 reports describing 49 pregnancies affected by pemphigus.257 
Prednisolone alone was used in 75% (37/49) of the cases at doses between 5 to 300 
mg/day. Adjuvant therapies were used in eight patients; azathioprine (n=5), plasmapheresis 
(n=1), plasma exchange (n=1) and dapsone (n=1). Five neonatal deaths were reported. 
Twenty (45%) of the neonates had pemphigus lesions at birth with all resolving within 4 
weeks either spontaneously or with mild topical corticosteroids. Overall, there seems to be 
an increased risk of foetal morbidity with gestational PV with higher preterm birth rates and 
low birth weight. There is no clear increased foetal loss.258 
 
The most commonly used treatments for pemphigus in pregnancy are oral corticosteroids. 
Current evidence suggests that there is no significant increased risk of stillbirth, preterm 
delivery or congenital malformations from using prednisolone in any disease, though the 
usual side effects of corticosteroid use will still occur.258 Both systemic and very potent 
topical corticosteroids have been linked with intrauterine growth retardation. Corticosteroids 
should be the first-line systemic agent. The type of corticosteroid used is important since 
prednisolone is 90% inactivated by the placenta whereas betamethasone and 




There are no prospective studies of immunosuppressant therapy for pemphigus in 
pregnancy. Many systemic immunosuppressive agents including mycophenolate mofetil, 
methotrexate and cyclophosphamide should be avoided due to known risks to the foetus.  
 
Azathioprine, in combination with corticosteroids, has been used successfully for 
pemphigus.257 Whilst there are risks of teratogenicity with azathioprine these are low and 
azathioprine has been widely used during pregnancy in association with renal 
transplantation, inflammatory bowel disease and systemic lupus erythematosus.259 
 
IVIG is safe in pregnancy. Ahmed et al. report eight patients with severe pemphigus in 
pregnancy. Seven responded well and one developed headaches and stopped treatment; 
none of the neonates had any erosions.159 Finally, plasmapheresis has been used 
successfully although this option is unavailable in many centres.260 
 
Rituximab has been used successfully in childhood pemphigus though its effects in 
pregnancy are uncertain.261-263 Rituximab is able to cross the materno-foetal barrier and the 
manufacturers advise against pregnancy for 1 year following rituximab therapy. The drug 
may affect the developing immune system potentially, and thus, the risks to mother and 
foetus need to be considered carefully prior to treatment. If a pregnancy is exposed to 
rituximab the baby should avoid live vaccines for at least the first 6 months of life.264 
 
Maternal IgG is excreted in human milk and women should not breastfeed whilst receiving 




Pemphigus occurring in pregnancy is rare. Data suggests that there is no increased risk of 
fetal loss although some morbidity is seen especially with respect to low birth weight. 
Prednisolone alone is the most common treatment. Certain second line treatments have 
been safely used when needed. 
 
 
23.0 PEMPHIGUS VULGARIS IN CHILDREN (Strength of recommendation D, level of 
evidence 3) 
 
Even though PV affects adults predominantly, it can occur in children. A recent review has 
suggested a further subdivision of this group into childhood PV, referring to disease in 
children younger than 12 years old, and juvenile PV, affecting adolescents aged between 12 
and 18 years.265 This sub-classification helps delineate the potential adverse effects of 
medications used in these subgroups. A self-limiting form of PV can occur in neonates born 
to mothers with PV, due to trans-placental transfer of autoantibodies.  
 
Systemic corticosteroids are the treatment of choice in both childhood and juvenile PV,67 but 
children are more susceptible to the potential adverse effects of corticosteroids compared to 
adults. Growth retardation is the most important adverse effects in children on long-term oral 
corticosteroids. In both children and adolescents, the height will need to be recorded 
regularly and expert advice is prudent if high-dose corticosteroids are used long-term. 
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Regular checks for signs of adrenal suppression are recommended ( 
http://cks.nice.org.uk/corticosteroids-oral#!scenario).266 
 
In a series of 33 patients with childhood PV, prednisone was used in 26; with the dose 
ranging from 12 to 500 mg/day (mean 88.3 mg/day). Other immunosuppressant medications 
used included gold (n=2), azathioprine (n=6), dapsone (n=4), cyclophosphamide (n=2), 
ciclosporin (n=1), rituximab (n=2), mycophenolate mofetil (n=1), and IVIG (n=1). Six patients 
(18.2%) achieved complete recovery and 78.8% (26/33) had partial remission, with minor 
relapses whilst on maintenance therapy. Of concern was the high rate of serious side 
effects, with cushingoid features in 65%, growth retardation in 50% and infection in 50%.267 
 
Juvenile PV has features similar to adult PV but disruption of biological and social 
development due to the skin disease raises particular concern during adolescence. The 
largest series of juvenile PV included 47 patients, with 42 requiring systemic corticosteroids. 
Corticosteroid-sparing agents used included azathioprine (n=1), intramuscular gold (n=1), 
dapsone (n=3), cyclophosphamide (n=2), mycophenolate mofetil (n=2), and rituximab (n=3). 
IVIG was reported in eight patients, for four of whom it was used as monotherapy. All 47 
patients responded to treatment, with adverse effects reported in 19%. Infection (8.5%), 
weight gain (10.6%), and cushingoid appearance (6.4%), were the main side effects, 
associated mainly with systemic corticosteroids.67,268 Relative youth may be a positive factor 
in terms of prognosis and mortality.268 
 
There have been only 18 anecdotal reports of the use of rituximab in PV affecting 
children.263,269-272 It may have a role in PV affecting children when treatment with systemic 
corticosteroids and other immunosuppressants have failed to confer any benefit. It has been 
used as monotherapy or in combination with systemic corticosteroids and other 
immunomodulatory drugs.  
 
IVIG therapy has been reported to be effective in children with juvenile PV.273,274 It can be 
used as monotherapy or in combination with other systemic agents.268 IVIG is an attractive 
second-line option for juvenile PV as the risk of thromboembolic events and renal failure are 
considered to be much less compared to adults.274 
 
Summary 
The course of PV in children is generally favourable, with a better prognosis compared to 
adult PV.263 Due to its rarity, there are no RCTs in the use of systemic agents in this 
condition. Overall, its treatment after initial systemic corticosteroids is similar to adult 
regimens and the same adjuvant therapies can be used.  
 
 
24.0 INDUCED PV 
Drugs can trigger pemphigus but this is uncommon. The diagnosis is challenging because 
drug-induced cases resemble idiopathic pemphigus, there are no clinical or laboratory tests 
that can distinguish reliably and the latency between starting the drug and disease onset can 
be several months. Therefore, a thorough drug history is essential, cross-checking against 
drugs reputed to trigger pemphigus (see Table 3).275,276 A poor response to standard 
























Table 3. Drugs reputed to trigger pemphigus275,276 
 
There are three groups of chemical structures which have been suggested to cause drug-
induced pemphigus: thiol drugs, which have a sulfhydryl radical; phenol drugs; and non-thiol, 
non-phenol drugs (see Table 3). PF is the most common pattern of DIP, observed in up to 
70% of thiol-induced cases. Non-thiol drugs tend to trigger a PV phenotype. Pruritus is more 
common in DIP than in idiopathic pemphigus.275,277 Diagnostic investigations are as for 
idiopathic pemphigus, with no immunopathological features in routine investigations that 
differentiate.278 
 
Initial management of DIP includes stopping the offending drug, possibly combined with 
conventional treatment in severe cases to hasten remission. Thereafter, it may follow two 
courses: the disease may continue in 50% in spite of drug withdrawal (drug-induced 
pemphigus) whilst the others recover completely (drug-triggered pemphigus).279 Recovery 
following drug withdrawal is more likely in thiol-triggered cases. In patients who do not remit 
upon drug withdrawal, the course and prognosis is similar to idiopathic disease and should 
be managed as such. 
 
 
25.0 PATIENT SUPPORT 
 
Patients should be directed towards reputable sources of information and support. A patient 
information leaflet is available on the BAD website (www.bad.org.uk/for-the-public/patient-
information-leaflets). In the UK, the PV Network (www.pemphigus.org.uk) and PEM Friends 
(UK) (www.pemfriends.co.uk) and internationally, the Pemphigus Pemphigoid Foundation 
(IPPF, www.pemphigus.org), are organisations providing patient support. Patients with PV 
may need psychological support to help them cope with coming to terms with a chronic, 
painful and visible disease or the impact of its treatment, particularly corticosteroids.280,281 
The input of a pain management team may be needed to advise on management of painful 
skin or mucosal lesions and the advice of a dietician if oral intake is impaired. 
 
 
26.0 FOLLOW-UP AND TAPERING OF TREATMENT 
 
Once remission is induced, there should follow a period of maintenance treatment using the 
minimum drug doses required for disease control and during which occasional blisters are 
acceptable. Drug doses should be reduced slowly (see section 12) and patients should 
remain under follow-up while they remain on therapy. Ultimately, treatment may be 
withdrawn if there has been prolonged clinical remission. The chances of relapse are 
reduced if immunofluorescence or ELISA studies are negative, e.g. the risk of relapse is 
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13% to 46% if DIF is negative, 44% to 100% if DIF is positive; 24% if IIF is negative, and 
57% if IIF is positive;282-284 25% if desmoglein 3 ELISA is negative, 56% if desmoglein 3 
ELISA is positive.285 In DIF-negative patients, there is some evidence to suggest that relapse 
is less likely the longer a patient has been in remission on minimal therapy prior to stopping 
treatment; 46% in all DIF-negative patients, 22% in those in remission for 6 months and 0% 
with remission of over 12 months.284 However, DIF can remain positive occasionally in 
patients who are in remission and off all treatment.21 A less invasive and relatively simple 
alternative to DIF on a skin biopsy, in this situation, is DIF on the outer root sheath of 
plucked hairs.286 This investigation is not widely available at present. 
 
There is no evidence to guide the order in which treatments are reduced and withdrawn in 
PV. However, it is common practice to withdraw corticosteroids first,287,288 to minimize their 
side effects, whilst maintaining adjuvant immunosuppressants at full dose (see section 12 for 
guidance on the rate of dose reduction). Thereafter, adjuvant drugs can be tapered slowly if 
remission is maintained. If complete treatment withdrawal is successful, and the patient 
remains in complete remission for a prolonged period, discharge to their primary care 
physician is reasonable but patients and their carers should be warned that PV can recur, in 
which case they should be referred to secondary care immediately. 
 
 
27.0 FUTURE DIRECTIONS 
 
As these guidelines illustrate, there is a lack of high-quality evidence supporting the use of 
many drugs in PV. Even answering the basic question of whether there is benefit in adding 
adjuvant immunosuppressants to corticosteroids is not clear-cut for most drugs. The 
answers to these questions will only come from large, multicentre RCTs which would need to 
be of sufficient length to demonstrate the long-term outcomes that are of relevance in this 
chronic disease.  
 
The role of biologics and their place in the management of PV is an area of great interest. So 
far, mMost experience comes from treating patients with established disease resistant to 
standard treatment.. It is interesting to speculate whether using rituximab, or newer anti-
CD20 drugs, as a first-line drug in newly presenting, treatment-naïve patients, might offer 
better long-term outcomes compared with the standard approach of corticosteroids with an 
adjuvant immunosuppressant. Such potential advantages might offset its additional cost in 
the long-term. A recent unbleinded RCT has shown that rituximab combined with 
prednisolone is more effective than prednisolone only in newly diagnosed patients.45 Further 
studies to confirm this result and to compare with corticosteroid/immunosuppressant 
combinations are awaited. 
 
The development of anti-CD20 drugs that can be self-administered by subcutaneous 
injection also has the potential to be a very useful step forward. At present, ongoing trials 
using rituximab and ofatumumab may help answer some of these questions and positive 
results may lead to formal licensing, making use of these drugs more straightforward. In 
2016, NHS England approved routine commissioning of rituximab in the treatment of 
pemphigus that has failed to respond to systemic steroids together with adjuvant 




content/uploads/sites/12/2013/04/16035_FINAL.pdf), thereby ensuring consistent access 
and funding across the UK National Health Service in England. This document was 
produced prior to the recent RCT using rituximab.45   
 
Further investment in diagnostic laboratories is needed to enable routine use of tests such 
as immunoprecipitation to enable more precise diagnosis of pemphigus subtypes leading to 
better targeted investigation and treatment 
 
 
28.0 RECOMMENDED AUDIT POINTS 
 
In the last 20 consecutive patients with PV, or all patients seen in the last 12 months (if less 
than 20), is there clear documentation of: 
 
1. Measurement of baseline parameters prior to starting treatment 
As a minimum this should include: 
 Weight  
 Blood pressure and whether there is a clinical history of hypertension 
 Height (children) 
 Blood glucose and HbA1c and whether there is a clinical history of 
diabetes 
 Pregnancy test (if appropriate) 
 Full blood count, renal and liver function tests 
 
2. Appropriate investigations to establish diagnosis 
As a minimum this should include: 
 A lesional skin/mucosal biopsy for routine histopathology 
 Perilesional skin/mucosal biopsy for direct immunofluorescence 
(alternatively, indirect immunofluorescence or desmoglein ELISA if 
biopsy is not possible) 
3. Evidence of appropriate drug monitoring 
For patients on corticosteroids, as a minimum this should include regular 
measurements of or documentation of: 
 Blood pressure 
 Weight  
 Blood glucose/HbA1c 
 Height (children) 
 Renal function 
 Evidence that gastric and bone prophylaxis is considered 
 Symptoms suggestive of important side effects, e.g. peptic ulceration, 
visual decline 
 
Other investigations are dependent on the choice of adjuvant drug but should 
include documentation of baseline investigations relevant to the drug in question 
and evidence of appropriate follow-up monitoring.  
 





5. Use of objective disease-scoring methodologies to assess clinical outcomes, e.g. 
the pemphigus disease area index, the autoimmune bullous skin disorders 
intensity index or the oral disease severity score.31-35 
The usual audit recommendation of 20 cases per department is to reduce variation in the 
results due to a single patient, and allow benchmarking between different units. However, 
departments unable to achieve this recommendation may choose to audit all cases seen in 





(See full manuscript for details of evidence) 
 
Table 4 summarizes the treatment options for PV, highlighting certain practical and 
economic considerations. For an overview of PV management to serve as a brief summary 




Additional supporting information including administration of rituximab and the search 
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(Level of evidence) 
Drug Indication(s) Advantages Disadvantages Principal side effects 
B (1+) Oral corticosteroids The cornerstone of 
therapy; effective;  
optimum dosing 
schedule not known 




Side effect profile 
 
Diabetes; osteoporosis; adrenal 
suppression; peptic ulceration; weight 
gain; increased susceptibility to 
infection; mood changes; proximal 
myopathy; Cushing’s syndrome; 
cataracts 
B (1+) Azathioprine 
 
Commonly used in 
combination with oral 
corticosteroids for 
steroid sparing effect; 
monotherapy may be 






side effect profile 
 
Myelosuppression and nausea (related 
to thiopurine methyltransferase activity); 
hepatotoxicity and hypersensitivity 
reactions (unrelated to thiopurine 
methyltransferase activity); increased 
susceptibility to infection 
B (1+) Mycophenolate 
mofetil 




tolerated and possibly 







(mycophenolic acid may be used as an 
alternative); lymphopaenia; anaemia; 
neutropaenia; trombocytopaenia; 
increased risk of infections 
B (1+) Rituximab Patients intolerant of 
or refractory to 
conventional CS 
together with adjuvant 
immunosuppression 
Effective; long lasting 
effect 
Cost; infection risk; 
infusion reactions* 
Risk of infection; risk of reactivation of 
hepatitis B; risk of precipitation of 
progressive multifocal 
leukoencephalopathy due to the JC 
virus; 
Hypogammaglobulinaemia (rare); late 
onset neutropenia; development of 
neutralising antibodies; 
Infusion reactions are generally mild; 
anaphylaxis is rare 
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Consider for severe or 
recalcitrant PV; 
repeated courses; 
may not be practical  
Possibly less steroid 






intensive; risk of bladder 
malignancy and infertility 
 
Alopecia, infections; infertility; 
haemorrhagic cystitis; acne; hiccup 




maintenance agent for 
recalcitrant PV failed 
on other regimens; 
could be considered in 
severe cases to 
induce remission 
whilst slower-acting 
drugs take effect 
Rapid action reported 
in some cases; no 






intensive; theoretical risk 
of blood-borne virus 
infections 
During infusion, chills, tachycardia, 
hypertension, muscle pains, pyrexia, 
nausea and headache are common, 
self-limited and respond to slowing the 
infusion; anaphylaxis is rare (increased 
risk in IgA deficiency) 
 
B (2++) (1+) Rituximab Patients intolerant of 
or refractory to 
conventional CS 
together with adjuvant 
immunosuppression 
Effective; long lasting 
effect 
Cost; infection risk; 
infusion reactions* 
Risk of infection; risk of reactivation of 
hepatitis B; risk of precipitation of 
progressive multifocal 
leukoencephalopathy due to the JC 
virus; 
Hypogammaglobulinaemia (rare); late 
onset neutropenia; development of 
neutralising antibodies; 
Infusion reactions are generally mild; 
anaphylaxis is rare 
D (3) Extracorporeal 
photophoresis 
May be considered in 
recalcitrant disease 
where conventional 
treatment has failed 







limited availability; limited 
data; ultraviolet 
protective sunglasses on 
the day of treatment; 
venous access can be a 
problem 





D (3) Gold  More commonly used 
as an adjuvant, 
enabling steroid dose 
reduction; an 







slow onset; not 
commonly used 
 




D (3) Immunoadsorption Should be reserved 
for the treatment of 
patients resistant to or 
intolerant of other 
approaches and 
should be used in 
combination with 




aimed at rapidly 
decreasing 
pathogenic antibody 





Hypotension, anaphylaxis, sepsis 
D (3) Methotrexate Could be used as an 
adjuvant drug if others 













D (3) Oral 
Cyclophosphamide  
Could be considered 
as an alternative to 
azathioprine and 
mycophenolate mofetil 
if secondary infertility 




Potential risk of 
haemorrhagic cystitis 
and carcinoma of bladder 
Neutropaenia; alopecia;  
gastrointestinal disturbances; raised 
transaminases; thrombocytopaenia; 
secondary infertility; nausea 
D (3) Plasma Exchange 
and Plasmapheresis 
Not recommended as 
routine; may be 
considered for difficult 
cases if combined 
with steroids and 
immunosuppressants 
Direct and immediate 
removal of IgG and 
therefore removal of 
PV antibodies 
 
Central venous access; 
specialist equipment; 
trained staff; limited 
availability; labour-
intensive; expensive; 
rebound production of 
PV antibodies after PE  








Gold  More commonly used 
as an adjuvant, 
enabling steroid dose 
reduction; an 







slow onset; not 
commonly used 
 




D(GPP) (4) Pulsed intravenous. 
corticosteroids 
Consider for remission 
induction in severe or 
recalcitrant disease, 
particularly if 






Mood changes; flushing. 
Not recommended  
(-1) 
Ciclosporin   Side effects; expensive  
 
Hypertension; renal impairment; 
Gastrointestinal disturbances; 
hypertrichosis; hypertrophic gingivitis 
Insufficient evidence 
(3) 
Chlorambucil Although may be used 
in practice further 










Dapsone  Although may be used 
in practice further 










Although may be used 
in practice further 




Frequent dosing (2 
tablets twice daily) 








nicotinamide could be 
considered as an 
adjuvant in milder PV 
Inexpensive 
 
Lots of tablets 
 
Flushing and headaches due to 
vasodilation with nicotinamide; 
gastrointestinal upset (tetracyclines); 
hyperpigmentation, particularly at sites 
of blistering (minocycline); 
discolouration of teeth (avoid 
tetracyclines in children and 
pregnant/lactating females) 
 
Table 4: Summary of treatment options for the management of pemphigus vulgaris (PV) 






LEVELS OF EVIDENCE 
Level of evidence Type of evidence 
1++ 
High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a 
very low risk of bias 
1+ 
Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs 
with a low risk of bias 
1- 
Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of 
bias* 
2++ 
High-quality systematic reviews of case-control or cohort studies 
High-quality case-control or cohort studies with a very low risk of 
confounding, bias or chance and a high probability that the relationship 
is causal 
2+ 
Well-conducted case-control or cohort studies with a low risk of 
confounding, bias or chance and a moderate probability that the 
relationship is causal 
2- 
Case-control or cohort studies with a high risk of confounding, bias or 
chance and a significant risk that the relationship is not causal* 
3 Non-analytical studies (for example, case reports, case series) 
4 Expert opinion, formal consensus 
*Studies with a level of evidence ‘-’ should not be used as a basis for making a 
recommendation 
 
STRENGTH OF RECOMMENDATION 
Class Evidence 
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly 
applicable to the target population, or 
A systematic review of RCTs or a body of evidence consisting principally of 
studies rated as 1+, directly applicable to the target population and 
demonstrating overall consistency of results 
Evidence drawn from a NICE technology appraisal 
B A body of evidence including studies rated as 2++, directly applicable to the 
target population and demonstrating overall consistency of results, or 
Extrapolated evidence from studies rated as 1++ or 1+ 
C A body of evidence including studies rated as 2+, directly applicable to the target 
population and demonstrating overall consistency of results, or 
Extrapolated evidence from studies rated as 2++  
D Evidence level 3 or 4, or 
Extrapolated evidence from studies rated as 2+, or 
Formal consensus 
D (GPP) A good practice point (GPP) is a recommendation for best practice based on the 
experience of the guideline development group 
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